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Abstract 
The discovery that most mammalian genome sequences are transcribed to RNA has revolutionized 
our understanding of the mechanisms governing key cellular processes and of the causes of human 
diseases, including diabetes mellitus. Pancreatic islet cells were found to contain thousands of non-
coding RNAs, including microRNAs, Piwi-associated RNAs, small nucleolar RNAs, tRNA-
derived fragments, long non-coding RNAs and circular RNAs. While the involvement of 
microRNAs in islet function and in the etiology of diabetes is now well documented, there is 
emerging evidence indicating that other classes of non-coding RNAs are also participating in 
different aspects of islet physiology. The aim of this review will be to provide a comprehensive 
and updated view of the studies carried out in human samples and rodent models over the last 15 
years on the role of non-coding RNAs in the control of α- and β-cell development and function and 
to highlight the recent discoveries in the field. We will not only describe the role of non-coding 
RNAs in the control of insulin and glucagon secretion but will also address the contribution of 
these regulatory molecules in the proliferation and survival of islet cells under physiological and 
pathological conditions. It is now well established that most cells release part of their non-coding 
RNAs inside small extracellular vesicles allowing the delivery of genetic material to neighboring 
or distantly located target cells. The role of these secreted RNAs in cell-to-cell communication 
between β-cells and other metabolic tissues as well as their potential use as diabetes biomarkers 
will be discussed.  
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Didactic synopsis 
Major teaching points:  
 - Several classes of non-coding RNAs, including miRNAs, piRNAs, snoRNAs, tRFs, 
lncRNAs and circRNAs, are expressed in islet cells. 
 - Bioinformatics tools have been developed to identify new non-coding RNAs, to 
understand their mode of action and to predict their targets.  
 - Non-coding RNAs are essential regulators of pancreatic development, β-cell 
differentiation and maturation.  
 - Dysregulation of non-coding RNAs has been observed in islets of diabetic animal models 
and diabetic human donors. 
 - Non-coding RNAs can be released in extracellular vesicles and transferred to other islet 
cells or to metabolic organs to regulate glucose and insulin homeostasis.   
 - Circulating non-coding RNAs represent promising biomarkers. 
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Introduction  
Diabetes mellitus is a metabolic disorder currently affecting about 8% of adults around the world 
(https://www.idf.org/). Population aging and obesity pandemics is expected to dramatically 
increase diabetes incidence in the coming decades. Diabetes mellitus is an important risk factor for 
a variety of other disorders and constitutes a major public health concern (15, 136). Indeed, if 
untreated, diabetes can lead to devastating long-term complications that significantly affect life 
expectancy and quality. These include heart and kidney failure, stroke, neuropathic pain, blindness 
and lower limb amputations.  
Diabetes mellitus is characterized by chronically elevated blood glucose levels resulting 
from the release of insufficient insulin to cover the organism needs. Pancreatic β-cells are the only 
source of this essential anabolic hormone that governs glucose uptake in skeletal muscles and 
adipocytes, and glucose production and storage in hepatocytes. Diabetes mellitus can have different 
etiologies but all forms of the disease are associated with dysfunction and/or loss of the insulin-
secreting cells (Fig. 1). Type 1 diabetes (T1D), representing about 10% of the diabetes cases, is 
caused by an autoimmune reaction directed against the β-cells (15). Since the immune attack results 
in a near complete elimination of the β-cells, the individuals suffering from this form of the disease 
necessitate multiple daily insulin injections. Type 2 diabetes (T2D) is the most frequent form of 
the disease (~90% of the diabetes cases). It is usually associated with obesity and results from the 
failure of β-cells to compensate for a diminished sensitivity of insulin target tissues (136). Usually, 
this form of the disease is treated with drugs that increase the sensitivity of insulin target tissues 
and/or stimulate insulin secretion, but part of the patients may also require daily insulin injections. 
Gestational diabetes is a form of the disease occurring in about 5%-10% of the pregnancies and 
usually resolves after delivery (247). However, women suffering from gestational diabetes as well 
as their offspring have a higher propensity to develop T2D later in life. While diabetes mellitus 
usually results from a combination of metabolically inappropriate environmental conditions and 
unfavorable genetic background, the disease can also be caused by mutations in single genes. These 
monogenic forms of the disease can manifest already at birth (neonatal diabetes) or appear much 
later in life (maturity onset diabetes of the young).  
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Involvement of pancreatic islets in glucose homeostasis and in diabetes development   
Pancreatic β-cells are highly specialized cells localized within the islets of Langerhans, which 
contain also α-cells (secreting glucagon), δ-cells (secreting somatostatin) and ε-cells (secreting 
ghrelin). β-cells are the only cells in the body capable of producing and secreting insulin in response 
to a rise in blood glucose levels. This peculiar property is only acquired after a complex maturation 
process that is completed during the neonatal period. Indeed, newborn β-cells are capable of 
producing appropriate amounts of insulin but are still inefficient in secreting the hormone in 
response to elevated glucose levels (5, 6, 18, 96, 124). This unique functional feature involves the 
activation of specialized metabolic pathways that are only fully operational after a neonatal gene 
reprogramming. Beside differences in the secretory properties, newborn β-cells display also a 
proliferation rate that is much higher than that of adult β-cells (124, 213). This permits an important 
expansion of the insulin-secreting cells during the neonatal period (Fig. 1). β-cell proliferation 
strongly declines thereafter and is almost undetectable in adults, particularly in humans (327). 
Thus, defects in the events necessary for the expansion and the functional maturation of the β-cells 
occurring early in life can potentially impact on the capacity to meet conditions of increased insulin 
demand occurring later in life such as pregnancy or obesity, predisposing to the development of 
gestational diabetes and T2D at adulthood (Fig. 1) (236).  
The molecular mechanisms triggering the autoimmune attack of the β-cells in T1D or 
underlying the failure of β-cells to compensate for insulin resistance in T2D or gestational diabetes 
remain to be fully elucidated. In the last decades, large efforts have been undertaken to determine 
the contribution of changes in gene expression in the development of different forms of diabetes. 
Most of these investigations focused on genes coding for proteins that play essential roles in β-cell 
differentiation and/or function. However, protein-coding genes account for less than 2% of the 3.2 
billion base pairs constituting the human genome and we now know that the majority of the genome 
sequences can be transcribed to RNA (1, 141). Consequently, mammalian cells contain a very large 
number of RNA molecules without coding potential (Fig. 2) that are emerging as important 
regulators of many physiological and pathological processes, including diabetes development (37, 
224). These recently discovered non-coding RNAs (ncRNAs) are categorized according to their 
length and physico-chemical properties (Fig. 3). Small ncRNAs are shorter than 200 nucleotides 
and include RNAs with regulatory functions such as microRNAs (miRNAs), Piwi-associated 
RNAs (piRNAs), small nucleolar RNAs (snoRNAs) and tRNA-derived fragments (tRFs). Long 
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non-coding RNAs (lncRNAs) are longer than 200 nucleotides and constitute a heterogeneous class 
of transcripts. Until recently, the mammalian transcriptome was thought to be formed almost 
exclusively by linear transcripts. However, in depth analysis of high throughput sequencing data 
combined with ad hoc computational approaches highlighted the presence of thousands of circular 
RNAs (circRNAs) originating from both exons and introns of protein-coding genes (114, 160, 170). 
Since most circRNAs are longer than 200 nucleotides, they are sometimes considered as a subgroup 
of lncRNAs. Contrary to miRNAs, the function and mode of action of piRNAs, snoRNAs, tRFs, 
lncRNAs and circRNAs are just starting to be uncovered, but there is already evidence for their 
involvement in several human diseases, including diabetes (28, 40, 160, 233, 292). Other classes 
of ncRNAs will most probably emerge in the coming years, completing the broad picture of this 
RNA family. For example, enhancer RNAs (eRNAs) that were initially thought to be the result of 
transcriptional noise were recently shown to have enhancer function (183, 335). The role of this 
particular ncRNA family in islet physiology remains however to be investigated. 
The aim of this review will be to provide a comprehensive and updated picture of the role 
of miRNAs, piRNAs, snoRNAs, tRFs, lncRNAs and circRNAs in the control of islet function and 
in the development of diabetes mellitus. The major challenge of this comprehensive review was to 
discuss the contribution of many classes of ncRNAs in a variety of islet functions since each 
ncRNA class is involved in many aspects of islet biology, and most physiological or pathological 
conditions are affected by several types of ncRNAs. Since part of the readers will be mainly 
concerned by selected classes of ncRNAs while others will focus on specific physiological or 
pathological conditions, we will first discuss the general involvement of each class of ncRNAs in 
islet biology. The following sections will then describe in more detail the role of ncRNAs in 
specific physiological or pathological conditions. Finally, the last two sections will briefly 
summarize the literature on extracellular ncRNAs and the therapeutic potential of ncRNAs for 
diabetes treatment and will discuss the obstacles that need to be overcome before considering their 
introduction in the clinic.   
Identification and function of non-coding RNAs in pancreatic islets under physiological 
conditions 
miRNAs  
miRNAs are small RNA molecules of 21-23 nucleotides that regulate post-transcriptional gene 
expression by binding to the 3’ untranslated regions (UTR) of target messenger RNAs (21). These 
7 
 
small ncRNAs are produced from 70 nucleotide-long RNA transcripts forming a hairpin structure 
that is successively cleaved by the endonucleases Drosha and Dicer to yield a 21-23 nucleotide 
double-stranded RNA. Once separated, one of the strands (guide strand) binds to an Argonaute 
(Ago) protein and is uploaded into the RNA-induced silencing complex (RISC), permitting the 
recognition of complementary sites within the 3’UTRs of target mRNAs (21). This class of 
ncRNAs has been initially discovered in Caenorhabditis elegans in 1993 (178, 332) but has now 
been extensively studied also in vertebrates and plants (10, 22). Thousands of miRNAs have been 
identified in mammals and collectively regulate the expression of up to 60% of the human 
transcripts. In fact, each miRNA can silence the expression of hundreds of genes and every 
transcript can be regulated by several miRNAs (83, 284). Therefore, miRNAs are involved in the 
regulation of most cellular pathways and their dysregulation has been observed in several diseases, 
including diabetes.  
 
The importance of the miRNA network in islet physiology has been demonstrated by 
genetic modification of Dicer1 and Ago2 in different mouse models. Downregulation of Dicer1 
impaired pancreas development and β-cell maturation and function (see Section titled “Pancreatic 
islet development and β-cell differentiation”) (137, 140, 197, 203, 214) while specific knockdown 
of Ago2 under the control of the insulin promoter decreased the β-cell mass but favored insulin 
release and improved glucose tolerance (306). Opposite results were obtained in mice 
overexpressing Ago2 in β-cells (306). Since the first report in 2004 (254), a large number of 
miRNAs have been reported to be involved in the regulation of β-cell functions. Several high 
quality and exhaustive reviews have already been published on this topic (72, 78, 99, 169) and 
include a detailed list of the different models used to investigate the function of theses miRNAs in 
the context of islet physiology. Herein, we will focus exclusively on miRNAs for which a role in 
mature β- or α-cells has been confirmed in vivo, in human islets and/or by several research group 
and the next sections will cover the role of miRNAs in different aspects of islet physiology and 
pathophysiology.  
Involvement of specific miRNAs in the control of β-cell functions 
miR-375 
Poy et al. were the first to establish a role for miR-375, one of the most abundant and islet-enriched 
miRNAs, in the regulation of β-cell function. Silencing of mir-375 increases glucose-stimulated 
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insulin secretion in pancreatic β-cell lines and isolated mouse β-cells (254). Two independent 
studies identified myotrophin (MTPN) and PDK1, a key component of the PI3K signaling pathway 
whose reduction leads to a drop in insulin gene transcription, as direct targets of miR-375. Both, 
MTPN and PDK1 mRNA and protein levels are strikingly reduced upon miR-375 overexpression 
in insulin-secreting cell lines (65, 254). A follow up study showed that at 8 and 12-weeks of age, 
mice lacking mir-375 (375KO) display fed and fasting hyperglycemia, respectively (255). Insulin 
sensitivity and plasma insulin levels were unaffected in these animals and measurements performed 
on isolated islets revealed that the hyperglycemia observed in 375KO mice is not due to defective 
insulin secretion but rather to elevated glucagon secretion and plasma glucagon levels in both fasted 
and random-fed states. Morphological analysis of the islets of 375KO mice revealed a 31% 
decrease in the β-cell mass and an increased proportion of α-cells. These results indicate that 
375KO mice hyperglycemia is primarily caused by hyperglucagonemia resulting from the 
expansion of the α-cell mass (255) (see Section title “Involvement of miRNAs in the control of 
α-cell functions”). Finally, miR-375 was also found to be important for proper pancreas 
development (see Section titled “Pancreatic islet development”).  
 
miR-7 
miR-7 family members are highly conserved throughout evolution and are abundantly expressed 
in pancreatic islet cells. Two independent studies revealed that miR-7 is a negative regulator of 
insulin secretion in β-cells (172, 340). Latreille et al. reported that conditional inactivation of mir-
7a-2 in β-cells results in an increase in insulin exocytosis and in improved glucose tolerance (172). 
Indeed, miR-7 was found to directly bind to the 3’UTR of mRNAs coding for central regulators of 
vesicle fusion (Snca, Cspa, and Cplx1), cytoskeleton rearrangement (Pfn2, Wipf2) and membrane 
targeting (Zdhhc9). Accordingly, mRNA and protein levels of these secretory components were 
reduced in β-cells overexpressing miR-7a (158, 172). Transgenic mice overexpressing mir-7a-2 
selectively in β-cells (Tg7a2) developed diabetes due to impaired insulin secretion and β-cell 
dedifferentiation (172). These animals exhibited marked hyperglycemia, reduced plasma insulin 
levels, and impaired insulin secretion, while the α/β-cell ratio was unchanged. The expression of 
Ins1 and Ins2 as well as of Pdx1, Nkx6-1, Mafa, Pax6, and Neurod1, a group of transcription factors 
promoting β-cell differentiation and identity, were reduced in islets of adult Tg7a2 mice. Pax6 and 
Gata6 were identified as direct targets of miR-7. Interestingly, a reduction of about 80% of miR-
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7a selectively in β-cells, resulted in improved glucose tolerance due to increased insulin release 
(172). As discussed in the next Sections, miR-7 expression was found to regulate the development 
and differentiation of pancreatic endocrine cells and the expansion of the β-cell mass, and to be 
modulated in islets of diabetic animal models and human donors.   
 
miR-204  
Xu et al. demonstrated that TXNIP, a sensor of glucose and oxidative stress, induces miR-204 
expression by repressing signal transducer and activator of transcription 3 (STAT3) (339). 
Moreover, miR-204 was found to inhibit insulin promoter activity and to reduce insulin mRNA 
levels by targeting the transcription factor MafA. Successive studies performed by the same group 
demonstrated that miR-204 regulates ER stress and β-cell apoptosis by targeting PERK (338).  
Glucagon-like peptide 1 receptor (GLP1R) agonists are widely used for the treatment of 
diabetic patients in order to potentiate insulin secretion induced by elevated glucose concentrations. 
However, the efficiency of these compounds is dependent of the expression of GLP1R which is 
reduced in diabetic patients. Interestingly, GLP1R was identified as a direct target miR-204 and 
the levels of this miRNA were found to be increased in the islets of different mouse models of 
obesity and/or diabetes (339), but not in the islets of T2D human donors (138). Whole body deletion 
of mir-204 in mice (miR-204-KO) resulted in increased expression of islet GLP1R, improved 
glucose tolerance and augmented insulin secretion in response to a combination of high glucose 
and the GLP1R agonist Exendin-4 (132). Moreover, miR-204-KO mice were protected against 
diabetes development induced by multiple injections of low doses of streptozotocin (see also 
Section title “Type 1 Diabetes”). Since TXNIP was previously identified as a regulator of miR-204 
expression, the authors verified that β-cell specific deletion of Txnip led to reduce levels of miR-
204 with a concomitant increase of GLP1R and enhanced insulin release in response to glucose 
combined to Exendin-4. Taken together, these results suggest a link between TXNIP, miR-204 and 
incretin action on β-cell function. 
 
miR-17-92/miR-106b-25 cluster 
Lu et al. observed increased expression of miR-17 in MIN-6 cells treated with elevated glucose 
concentrations which led to direct inhibition of Menin, a well-established negative regulator of β-
cell proliferation (195). These data are in agreement with the reported positive impact of miR-17 
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in the expansion of the β-cell mass occurring during the neonatal period (124). Recently, 
Mandelbaum et al. confirmed these data in vivo using a conditional mouse model in which the miR-
17-92/miR-106b-25 cluster was deleted (202). These mice displayed a reduced β-cell mass and up 
to 50% reduction in total pancreatic insulin content. Detailed investigations revealed that the miR-
17-92/miR-106b-25 cluster does not regulate G1/S transition or G2/M checkpoint but is rather 
involved in the M phase. Along with reduced β-cell mass, miR-17-92/miR-106b-25-KO mice 
displayed defective insulin release in vivo and ex vivo in isolated islets (202). The positive impact 
of miR-17-92/miR-106b-25 clusters on β-cell proliferation seems to be maintained throughout 
different maturation cell stages, from immature newborn β-cells to adult β-cells (124, 202). In 
contrast, while inhibition of miR-17-92/miR-106b-25 in isolated islets of newborn rats promoted 
the acquisition of β-cell capacity to release insulin in response to glucose, blockade of these 
miRNAs in adult mice restrained insulin secretion through the regulation of a yet unknown 
metabolic process upstream to cell membrane depolarization (202). miR-17 can also promote β-
cell survival under inflammatory conditions. As described above, TXNIP is an important regulator 
of cellular redox state and its deletion in mice prevents β-cell apoptosis and diabetes appearance. 
miR-17 has been shown to target Txnip mRNA (180) and miR-17 overexpression was able to blunt 
cytokine-induced TXNIP activation in β-cells (115). Of note, the pro-inflammatory cytokines IL-
1β and IFNγ display opposite effects in the regulation of TXNIP, since IL-1β prevents Txnip 
expression by inhibiting ChREBP-mediated transactivation, while IFNγ increases Txnip expression 
via activation of IREα. In another cell model, IREα was found to rapidly diminish miR-17 stability 
(315), suggesting a regulatory loop between miR-17 and TXNIP expression that could be of 
importance in the prevention of cytokine-induced β-cell death and diabetes susceptibility. 
 
miR-200 family 
The miR-200 family is highly expressed in pancreatic endocrine cells and includes five 
evolutionarily conserved members: miR-200a, miR-200b, miR-200c, miR-141 and miR-429. 
Except for miR-429, the other four members of the family are induced by TXNIP and are 
upregulated in islets of B6-obese mice compared to lean controls (79). Transgenic mice expressing 
mir-141/200c under the control of the rat insulin promoter develop severe hyperglycemia, which 
over time results in uncontrolled diabetes due to a drastic decrease in plasma insulin levels, 
pancreatic insulin content and β-cell mass (24). Glucose-stimulated insulin secretion was unaltered 
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in isolated islets of the mir-141/200c transgenic mice and in β-cell lines after overexpression of 
miR-200c. However, the mice expressing mir-141/200c displayed a 6-fold-increase of β-cell 
apoptosis. The pro-apoptotic activities were attributed to a direct repression of the pro-survival 
factors Dnajc3, Jazf1, Rps6kb1 and Xiap (24). Further investigations unveiled that overexpression 
of miR-200c modulates the activity of the Trp53 pathway and results in the up-regulation of pro-
apoptotic transcripts Bax and Bbc3 (encoding PUMA) (24, 79). These two genes are associated 
with a greater β-cell apoptosis and diabetes development (52, 212). To address whether Trp53 
inhibition can rescue miR-200c-induced β-cell death and diabetes, Belgardt et al. generated β-cell-
specific double transgenic mice, which overexpress Trp53-inhibiting SV40 T antigen and mir-
141/200c. These mice were protected against β-cell loss and did not develop T2D associated with 
mir-141/200c transgenic mice (24). Despite the double transgenic mice showed no hyperglycemia 
and a similar rate of β-cell death compared to control mice, the striking glucose intolerance of 
Rip141/200c mice was not completely rescued following Trp53 inhibition, suggesting the 
contribution of additional miR-200c-associated pro-apoptotic mechanisms independent of Trp53 
pathway (24, 79).  
 
miR-184 
MiR-184 expression is reduced in islets of insulin resistant animals and is further dropped in islets 
of diabetic animal models (see Sections titled “β-cell mass expansion during obesity and gestation” 
and “Type 2 Diabetes”) (231, 306). MiR-184 appeared to act as a negative regulator of β-cell 
proliferation and survival, without impacting on insulin release (231). Tattikota et al. further 
characterized the function of miR-184 in vivo. Mice invalidated for mir-184 displayed an increased 
β-cell mass consequent to exacerbated β-cell proliferation, reduced fasting blood glucose levels 
and elevated plasma insulin concentrations, resulting in improved glucose tolerance without 
affecting insulin sensitivity (306). The glutamate transporter Slc25a22 identified as a direct target 
of miR-184 is likely to play a major role in the effect of this miRNA on mitochondrial respiration 
and insulin secretion (223, 305). MiR-184 levels were also inversely correlated with Ago2, an 
essential component of the RISC complex, in the islets of human donors (306).  
miR-708 
This miRNA is transcribed from the first intron of the Chop-regulated gene Odz4 (264). 
Interestingly, the expression of miR-708, Odz4, and Chop is increased in islets cultured at low 
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glucose concentrations, suggesting a common mechanism of regulation between the miRNA and 
its hosting gene. The islets of mir-708-overexpressing mice displayed reduced insulin secretion, 
and decreased β-cell proliferation and survival. The effects of this miRNA were suggested to be 
driven by silencing Nnat, which codes for a protein localized in the ER and known to regulate 
intracellular Ca2+ levels and insulin release. Indeed, the expression of miR-708 was negatively 
correlated to that of Nnat in cultured islets as well as in islets of obese ob/ob mice. These results 
suggest a contribution of miR-708 in the altered secretory capacities of β-cells associated with the 
development of diabetes in ob/ob mice (264). 
 
Let-7 family 
The RNA-binding protein LIN28 can directly repress let-7 family members, which include nine 
slightly different miRNAs (232). Interestingly, global LIN28a overexpression in mice results in 
altered body size and increased glucose metabolism and insulin sensitivity (356). Pancreas-specific 
induction of let-7 in transgenic mice under the control of the Pdx1 promoter, confirmed that let-7 
overexpression reduces insulin secretion and results in impaired glucose tolerance (84). To test 
whether inhibition of let-7 was sufficient to prevent diet-induced glucose intolerance, C57BL/6 
mice fed a high-fat diet received weekly for 8 consecutive weeks a systemic injection of let-7 
antimiR. In contrast to control mice, antimiR-treated mice maintained a normal glucose tolerance. 
Nonetheless, the positive impact of antimiR-induced knockdown of let-7 on glucose metabolism 
is most likely due to increased insulin sensitivity rather than improved β-cell function. Indeed, 
systemic inhibition of let-7 resulted in enhanced insulin sensitivity, likely by restoring insulin 
receptor signaling pathway in muscles and liver (84, 357). Of interest, let-7 targets several genes 
containing SNPs associated with T2D and the control of fasting glucose in human genome-wide 
association studies (GWAS) (357). Therefore, Lin28/let-7 signaling may be a central regulator of 
glucose metabolism. However, further investigations in animal models with β-cell specific let-7 
invalidation are necessary to precisely define the contribution of insulin-secreting cells to the 
beneficial impact of let-7 silencing.  
 
miR-132 
This miRNA is produced from the miR-212/132 cluster located on mouse chromosome 11. Both 
miR-132 and miR-212 were reported by different groups to be upregulated in pancreatic islets of 
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obese and/or diabetic rodent models (69, 228, 231, 351) but not in islets from T2D human donors 
(27). The increased expression of miR-132 was also observed in mouse islets following partial 
pancreatectomy (229). Overexpression of miR-132 in rodent β-cells in vitro and in vivo promoted 
insulin secretion in response to glucose and other secretagogues, as well as increased β-cell 
proliferation and survival (228, 229, 231, 298) (also discussed in the Section titled “β-cell mass 
expansion during obesity and gestation”). Interestingly, overexpression of miR-212 was also found 
to favor insulin release in INS 832/13 cells (298). Mice with whole body knockout of mir-132/212 
showed normal glucose tolerance, but their β-cells displayed a limited capacity to increase their 
proliferative rate upon pancreatectomy, supporting a role for miR-132 in β-cell regeneration (229). 
Mechanistically, the positive impact of miR-132 on insulin secretion was suggested to be mediated 
by direct down-regulation of carnitine acylcarnitine translocase (CACT), a mitochondrial protein 
involved in β-oxidation (298). In contrast, the proliferative effect was attributed to the repression 
of Pten, a negative regulator of β-cell mass expansion (229). As discussed in the next Section, miR-
132 regulates also the proliferation and survival of α-cells.  
Involvement of miRNAs in the control of α-cell functions 
Pancreatic islets are intricate cell aggregates comprising α- and β-cells as main endocrine cell types, 
which secrete the counter-regulatory hormones glucagon and insulin in response to low or high 
levels of glucose, respectively. Similar to insulin, glucagon production and exocytosis is tightly 
regulated by multiple factors, including neuronal, paracrine, and cell autonomous signaling 
pathways (7). Diabetes is now established as a bi-hormonal disease rather than an "insulin-centric 
disorder," emphasizing the critical role of glucagon in the regulation of glucose homeostasis (7, 
314). MiRNAs are likely to be important players in the regulation of α-cell functions and glucagon 
release, but this issue remains largely unexplored (72). Drastic reduction of the α-cell number upon 
inactivation of the miRNA-processing enzyme Dicer1 in the developing mouse pancreas (197), 
emphasizes the need to unveil miRNA expression patterns and to define their roles in glucagon-
secreting-cells. 
A miRNA profiling performed in human FACS-sorted α- and β-cells identified 7 miRNAs 
(miR-146a, miR-181a, miR-192-3p/-5p, miR-194-5p, miR-221 and miR-708) enriched by more 
than 2-fold in α-cells versus 141 miRNAs more abundant in β-cells (151). Of the seven miRNAs 
identified in human α-cells, only miR-146a was confirmed to by enriched also in mouse FACS-
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sorted α-cells and in TC1-6 α-cell line (19, 62). In FACS-sorted mouse islet cells, 35 miRNAs 
displayed 2-fold higher levels in α-cells and 31 in β-cells (62) whereas 50 miRNAs were enriched 
in αTC1-6 cells compared to 74 miRNAs in the βTC1 cell line (19). Despite these discrepancies, 
these studies highlighted differences in the expression of several miRNAs, which could be 
important for proper function of α- and β-cells. For example, miR-483 is greatly enriched in mouse 
FACS-sorted β-cells and TC3 β-cells compared to α-cells (219). Interestingly, overexpression of 
miR-483 in MIN6 cells favored insulin secretion, while this miRNA repressed glucagon 
transcription and secretion in TC1-6 α cells by modulating IRS2 and SOCS3 expression at the 
protein level. More precisely, miR-483 favored IRS2 levels but suppressed SOCS3 in both cell 
lines (219). IRS2 is known to favor insulin secretion but to reduce glucagon secretion (12), while 
silencing of Socs3 positively correlates with insulin transcription and secretion in MIN6 β-cells 
(184) and inhibits glucagon secretion and transcription in TC1-6 α-cells (219). Therefore, these 
data suggest that miR-483 counter-regulates both insulin and glucagon release by modulating the 
activity of IRS2 and SOCS3 proteins. Another example is cMaf, a transcription factor expressed 
selectively in α-cells and controlling glucagon expression. This transcription factor is regulated by 
miR-200c, miR-182 and miR-125b which are enriched in β-cells, enabling cMaf repression. 
Indeed, downregulation of each of these miRNAs resulted in increased cMaf expression in MIN6 
β-cells while their overexpression in a TC6 α-cells led to reduced cMaf mRNA and protein levels 
(151).  
MiR-155 was also identified as a key player in co-regulating α- and β-cell physiology to 
improve the adaptive response of islet cells to insulin resistance (358). Invalidation of mir-155-5p 
in mutant mice lacking the LDL receptor favored the development of atherosclerosis, obesity and 
diabetes when the mice were fed on a cholesterol-rich diet. Moreover, these mice displayed reduced 
plasma insulin levels and pancreatic insulin content, and elevated plasma glucagon levels and 
pancreatic glucagon staining compared to mice fed on control diet. In vitro, overexpression of miR-
155-5p in human and murine islets, and in α- and β-cell lines promoted multiple changes in the 
level of key genes involved in insulin, glucagon and GLP-1 production and secretion. Moreover, 
increased levels of miR-155-5p in human islet cells and in MIN6 cells led to the up-regulation of 
IL-6 through direct regulation of the transcription factor MAFB. These results suggest that miR-
155-5p stimulates the expression and secretion of IL-6 in β-cells, which in turn promotes GLP-1 
production from α-cells (358). To better understand the regulation of glucagon secretion by 
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miRNAs, Zhang et al. (348) quantified the level of these small RNAs in islets of 12h-fasted, 
glucagonemic C57BL/6J mice. Using this approach, they found that the expression of miR-124a-
3p was strongly reduced while the level of its targets, the ionotropic glutamate receptors, iGluR2 
and iGluR3, which are located on α-cells (45), were elevated. Interestingly, similar results were 
obtained in vitro when mouse islets were exposed to 25 mM glucose for 72 h, a condition known 
to enhance glucagon secretion (348).  
Besides glucagon secretion, miRNAs are also important regulators of α-cell proliferation. 
As mentioned in the previous Section, downregulation of miR-375 promotes α-cell mass expansion 
and, consequently, results in enhanced fasting and fed plasma glucagon levels, increased 
gluconeogenesis and exacerbated hyperglycemia (255). Interestingly, treatment with liraglutide, a 
GLP1 receptor agonist commonly used in the treatment of T2D patients, raised miR-375 levels in 
TC1-6 α-cells and reduced those of TC-tet β-cells (341). Moreover, exposure to liraglutide 
impaired TC1-6 α-cell proliferation and survival, and, on the contrary, favored the proliferation 
and survival of TC-tet β-cells. These results are in line with previous reports indicating that 
liraglutide promotes β-cell functions and insulin release while repressing α-cell activities and 
preventing excessive glucagon release (90). According to the finding described above, part of these 
effects could be mediated by miR-375.  
To obtain a broader view on miRNA deregulation in islet cells under pre-diabetic condition, 
Dusaulcy et al. performed microarray analyses on FACS-separated α- versus β-cells from mice fed 
on a low fat diet (LFD) or high fat diet (HFD) (62). More than hundred miRNAs were found to be 
differently expressed between α- and β-cells in both diet conditions. In the α-cell fraction, HFD 
induced the dysregulation of 16 miRNAs, of which 14 were downregulated and 2 upregulated. 
Interestingly, 8 of the 14 decreased miRNAs were located in a common genomic Meg3/DLK1 
cluster. The authors focused on miR-132, a miRNA previously identified to be upregulated in islets 
of obese and/or diabetic animals (231, 351) (see Section title “β-cell mass expansion during obesity 
and gestation”). The observed rise of miR-132 in β-cells in response to HFD was confirmed, but 
the miRNA was found to be downregulated in α-cells (62). As was the case for β-cells (200, 231, 
285), the expression of miR-132 in primary mouse α-cells was shown to be modulated by cAMP 
and to favor proliferation and survival, without affecting glucagon secretion (62). In contrast, 
inhibition of miR-132 reduced α-cell proliferation and increased apoptosis. Therefore, reduced 
expression of miR-132 in glucagon-secreting cells of HFD mice is likely to restrain α-cell 
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proliferation and to promote apoptosis. This effect is important to balance the mass of α- and β-
cells in a pre-diabetes context in order to maintain glucose homeostasis. Indeed, a rise in miR-132 
levels contributes to compensatory β-cell mass expansion and to the increase in insulin secretion 
under insulin resistant conditions (228, 231). 
Investigating the role of miRNAs in β- and α-cells in parallel may provide precious 
information about the fine tuning of the two main cell types of pancreatic islets that are highly 
interdependent and release counter regulatory hormones. Henceforth, several miRNAs seem to 
have opposite effects on α- and β-cells in order to optimize the metabolic control. 
 
piRNAs 
P-element induced Wimpy testis (PIWI)-interacting RNAs (piRNAs) are 21-35 nucleotide long 
RNAs that constitute a distinct class of small ncRNAs. The biosynthesis and function of piRNAs 
are dependent on their interaction with Argonaute proteins of the PIWI subfamily. piRNAs carry 
2’-O-methyl-modified 3’ termini, and are processed from single-stranded precursor transcripts 
(242). In animals, piRNAs are predominantly expressed in the germ line. Two populations of 
piRNA clusters have been described in mammalian testis. The first cluster is transcribed 
embryonically. These fetal piRNAs bind and guide PIWI proteins to silence transposable elements 
and thereby protect the integrity of the genome (242). The second cluster is expressed postnatally 
in spermatogenic cells undergoing the first meiotic division at a substage called pachytene (86). 
These pachytene piRNAs lack transposon sequences. While a consensus function of pachytene 
piRNAs is lacking, they are shown to facilitate the progression of meiotic division by regulating 
gene expression via mechanisms reminiscent of somatic miRNAs (95).  
piRNAs and pancreatic islets 
A growing body of literature describes piRNA expression and function in somatic tissues, with 
mammalian studies focusing mainly on cancer development (201, 233, 268). Analyses carried out 
by Henaoui et al. illustrated that components of the piRNA pathway are also expressed in 
pancreatic islets (113). Indeed, two PIWI-like genes, Piwil2 and Piwil4 were detected in rat 
pancreatic islets and in FACS-sorted β-cells and their orthologues PIWIL2 and PIWIL4 were 
detected in human islets. The expression of these genes was much lower than in testis but was 
comparable to other somatic tissues such as adipose tissue, brain, liver and skeletal muscle. In 
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addition to the two piwi genes, several genes involved in piRNA biogenesis such as Henmt1, Mael, 
Ddx4, Pld6 and Prmt5 were identified in rat islets. Moreover, piRNA-specific microarray analyses 
of rat islets revealed the presence of 18’450 of the 40’000 analyzed piRNAs (113) (summarized in 
Table 1). Taken together, these findings suggest that the PIWI/piRNA pathway is active in 
pancreatic islets of rats and possibly humans.  
snoRNAs 
Small nucleolar RNAs (snoRNAs) form ribonucleoprotein complexes and are classified into two 
subfamilies, the C/D-box (SNORD) or H/ACA-box (SNORA), depending on their nucleotide 
motifs and their protein partners. Their canonical function is to guide post-transcriptional 
modifications on ribosomal RNAs (rRNAs) and small nuclear RNAs (snRNAs). These non-coding 
RNAs are therefore mainly present in nucleoli but some snoRNAs have recently been found in 
other cellular compartments in association with non-canonical protein partners. Additional 
functions have been suggested for snoRNAs, including regulation of mRNA abundance, alternative 
splicing, translational efficiency and tRNA methylation (reviewed in (28)). Furthermore, snoRNA-
derived RNAs (sdRNAs) were detected by advanced RNAseq technologies suggesting that some 
snoRNAs may act after being processed into stable shorter RNA species (28).  
snoRNAs and pancreatic islets 
The non-canonical roles of snoRNAs in pancreatic islets are just starting to be unveiled (see Table 
1). Lee et al. investigated the impact on glucose and insulin homeostasis of the deletion of 4 box 
C/D snoRNAs (U32a, U33, U34 and U35a) produced from introns of the protein-coding gene 
Rpl13a, without affecting RPL13a at both mRNA and protein levels (177). Homozygous Rpl13a 
snoRNA loss-of-function (Rpl13a-snoless) mice had similar body weight, fasting plasma glucose 
and insulin levels, and insulin sensitivity compared to control mice. Interestingly, Rpl13a-snoless 
mice showed increased insulin release in response to glucose both in vivo and ex vivo, leading to 
enhanced glucose tolerance. As previously observed in another cell model (217), Rpl13a-snoless 
islets were resistant to oxidative stress. Consequently, Rpl13a-snoless mice were protected against 
the development of hyperglycemia following a streptozotocin treatment or after crossing them with 
diabetic Akita and non-obese diabetic (NOD) mice (177).   
While comparing the impact of Snord116 loss-of-function in mice with clinical symptoms 
analogous to  Prader-Willi syndrome (PWS) patients, Burnett and colleagues observed an effect on 
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islet-cell development (see Section titled “Pancreatic islet development and β-cell differentiation”) 
(30) and proinsulin processing (31). PWS is caused by a loss of paternally expressed genes in an 
imprinted region of chromosome 15q and leads to hyperphagic obesity, central hypogonadism, 
growth hormone deficiency, hyperghrelinemia and relative hypoinsulinemia (11). Deletion of only 
the paternal allele of Snord116 in mice (Snord116p-/m+), reproduced most of the features of the 
phenotype observed in PWS patient (31). Interestingly, Snord116p-/m+ mice were normoglycemic 
but, as observed in PWS patients, they secreted a higher ratio of proinsulin/C-peptide in response 
to glucose. This increase may be caused by a defect in insulin maturation since the expression of 
both PC1 and PC2, two enzymes required to process proinsulin into insulin and C-peptide, were 
downregulated in Snord116p-/m+ islets (31).   
tRNA-derived fragments 
Transfer RNAs (tRNAs) are non-coding RNAs that help decode messenger RNA (mRNA) 
sequences into proteins. They function as carriers and adapters of amino acids between mRNAs 
and newly synthesized polypeptides. In most cells, approximately 12% of total RNA is comprised 
of tRNAs (243). There are over 260 different tRNAs in humans encoded by more than 400 genes.  
The average mammalian cytoplasmic tRNAs contain 13-14 modifications per tRNA, with 
methylation being one of the most commons (310). tRNA-modifying enzymes are present in the 
nucleus, cytosol or mitochondria, and modulate the function, folding and/or stability of the tRNA. 
tRNAs are the most stable RNAs in vivo, but hypomodified tRNAs are targeted for degradation 
(198). In addition to elimination of dysfunctional tRNAs by degradation, these ncRNAs may also 
undergo fragmentation induced by endonucleases (302). These tRNA fragments (tRFs) are 
evolutionarily conserved and subcategorized based on the region of the tRNAs they stem from. 
The most common types of tRFs are generated from the cleavage at either arms (12-20 nucleotide 
tRFs) or at the anticodon loop (32-50 nucleotide tRFs, also known as tiRNAs). Moreover, a double 
cleavage along the length of tRNAs generates internal tRNA fragments (16 nucleotides or longer, 
also known as i-tRFs). The generation of shorter tRFs is mediated by various endonucleases 
including Dicer, while generation of tiRNAs are mediated by Angiogenin (163) (Fig. 4).  
In recent years, in depth analyses of sequencing data, unveiled regulatory roles of tRFs in 
several cellular processes both in vitro and in vivo. So far tRFs have been shown to be implicated 
in stress responses and cancer (94, 302), cell-to-cell signaling via extracellular vesicles (43, 47, 
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107, 286), the response to viral infection (120), brain aging (142), and metabolic diseases (40, 50). 
The function of tRFs are diverse and may depend on the cell type, the condition, and the tRF 
subtype. The reported functions include the control of mRNA stability (94, 164), the regulation of 
translation and ribosome biogenesis through binding to ribosomal proteins and eIF4G/eIF4A (121, 
149), the protection of apoptosis through binding to cytochrome c (41, 273), and epigenetic 
regulations exerted by inhibiting the reverse transcription of endogenous retroviruses (280).  
tRFs and pancreatic islets 
Initial evidence potentially bridging tRFs to diabetes were obtained in sperm (40). In mice, HFD 
was shown to change the landscape of tRFs in sperm. Injection of tRFs isolated from HFD sperm 
into control zygotes altered the embryonic and islet transcriptome of the F1 offspring and 
predisposed these animals to glucose intolerance and insulin resistance. Using computational target 
predictions, the sperm tRFs differentially expressed in mice kept on HFD were predicted to match 
promoter regions of 62 impacted genes in early embryos. Among these were Maea, Ccnc, and 
Deptor, which have been reported to be involved in pancreatic β-cell function or to be associated 
with diabetic conditions (46, 57, 130). These results highlighted the potential impact of tRFs on 
pancreatic β-cell function.  
The role and the mechanisms of action of tRFs in the control of β-cell function under normal 
or pathophysiological conditions remains to be fully elucidated (summarized in Table 1). 
Highthroughput and unbiased analyses also need to be performed to measure their abundance in 
different rodent models and in human islets. However, as described in the Section titled “Type 2 
Diabetes”, there is now emerging evidence indicating that this newly described class of ncRNAs 
contributes to the regulation of the activities of insulin-secreting cells.  
Long non-coding RNAs 
LncRNAs include all linear transcripts of more than 200 nucleotides having no, or very low, 
protein-coding potential (252). This heterogeneous class of RNAs shares several characteristics 
with protein-coding mRNAs: they are transcribed by RNA polymerase II, they are capped, spliced 
and, in some case, polyadenylated, and their expression can be modulated by histone modifications 
(105, 106). They are mainly located in the nucleus but can also be found in the cytoplasm. 
LncRNAs are often classified based on their genomic proximity to protein-coding genes, for 
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example overlapping, intronic, cis-antisense or bidirectional (216) (Fig. 5). In contrast, long 
intergenic non-coding RNA (lincRNA) do not have relationship and do not share open reading 
frames with protein-coding genes. However, because of the vast heterogeneity of this class of RNA 
transcripts, a consensus on their nomenclature and classification is still missing (299).  
 Interestingly, compared to protein-coding RNAs and miRNAs, lncRNA expression is more 
tissue and developmental stage specific, suggesting that these transcripts may be involved in the 
fine-tuning of specialized cellular functions (56, 58). These ncRNAs can exert their regulatory 
activities at different levels in view of their capacity to bind other RNAs, DNA and/or proteins and 
to act as signals, guides, decoys and/or scaffolds (296) (Fig. 6). For example, lncRNAs can regulate 
chromatin organization and epigenetic modifications, modulate gene transcription or control 
mRNA processing by facilitating trans-chromosomal interactions, by recruiting epigenetic 
modifiers, by blocking the transcription factors access to gene promoters or by bringing in close 
proximity genes involved in similar biological pathways (108, 148, 205). LncRNAs can also 
increase mRNA stability, promote mRNA degradation, regulate mRNA translation and splicing 
(33, 74, 93, 311) or act as miRNA sponges (38, 251). LncRNAs can therefore be implicated in a 
wide variety of cellular mechanisms, and dysregulation in their expression has been associated with 
several diseases, including diabetes (70, 139, 227, 257, 292, 333). Finally, in addition to their non-
coding regulatory activities, some lncRNAs were found in different organisms to produce 
functional micropeptides, adding another layer of complexity to the role of these RNA molecules 
(182). However, none of these micropeptides have so far been reported in pancreatic islets.     
De novo annotation of lncRNAs specifically expressed in islets and β-cells 
The advent of ultra-deep RNA sequencing enabled the identification of islet- and β-cell specific 
lncRNA transcripts since these ncRNAs are generally expressed at low levels (56, 58). LncRNAs 
display restricted cell distribution and are less evolutionarily conserved than protein-coding genes 
with 30% of the human lncRNAs being primate specific (56). Before understanding the functional 
role of these non-coding transcripts, deep RNA sequencing of human and rodent islet cells followed 
by de novo annotation were necessary to identify the lncRNAs expressed in β-cells.  
  Moran and colleagues integrated sequence-based transcriptome and chromatin maps from 
human islet and FACS-purified β-cells and observed that 19% of the transcribed genome maps 
outside of annotated protein-coding genes (221). From this analysis, 1128 transcripts were selected 
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as islet-cell lncRNAs since they were detected in all samples, were longer than 200 nucleotides, 
had low protein-coding potential, did not overlap with any coding gene, and were generated from 
genomic loci showing enrichment of the transcriptionally active histone H3K4me3 mark. Of these, 
761 transcripts were antisense, 32 convergent, 335 were intergenic (lincRNAs) and 55 overlapping 
antisense. Importantly, the expression of all tested lncRNAs was confirmed in human islets by 
qPCR measurements and most of them were also detected in the human β-cell-line EndoC-βH1. 
While being expressed at lower levels compared to protein-coding genes, lncRNAs were found to 
be 4 to 5 times more islet-specific and some of them were actually solely detected in islet cells 
when a panel of 18 different tissues was analyzed (221). Similar results were also obtained upon 
de novo annotation of lncRNAs expressed in mouse islets and in FAC-sorted β-cells (162, 221, 
226). Furthermore, intergenic and antisense islet lncRNAs were often found to be located in the 
same genomic region as islet-enriched protein-coding genes, like HNF1A, PDX1, PAX6, NKX2.2, 
MAFB and FOXA2 (221).  
 While comparing the human and murine transcriptional landscape of FACS-purified β-
cells, Benner and colleagues identified a β-cell transcriptome core of more than 9’900 protein-
coding genes common between the two species (25). However, they observed marked differences 
between human and mouse lncRNA repertoire, confirming that also in β-cells these transcripts are 
more species-specific than protein-coding genes (25). As observed for human lncRNAs, some 
murine lncRNAs were found to be located in close vicinity of loci coding for important β-cell 
transcription factors, including Pdx1 and Nkx6.1. The expression of these lncRNAs and their 
neighboring protein-coding genes were co-enriched in β-cells over α-cells (25, 162). Finally, β-cell 
specific lncRNAs were found to be highly dysregulated in different mouse models of diabetes and 
in islets exposed to elevated glucose or cytokine concentrations, suggesting that lncRNAs may be 
implicated in β-cell dysfunction associated with diabetes (25, 226) (see Sections titled “Type 1 
Diabetes” and “Type 2 Diabetes”).  
Involvement of lncRNAs in the control of β-cell functions  
Among the thousands of lncRNAs identified in pancreatic islets, the precise role of only few of 
them has been so far unveiled in β-cells (see Table 1) (reviewed in (70, 139, 227, 257, 292, 333)). 
Here we elected to describe in detail only the role of HI-LNC15/βlinc1, PLUTO (HI-LNC71), HI-
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LNC78 and Meg3 for which the function has been investigated in human β-cells and/or in vivo in 
mice.   
HI-LNC15/βlinc1  
The function of the human HI-LNC15 (221) and its mouse orthologue βlinc1 (13) has been 
investigated both in vitro and in vivo (8, 13). HI-LNC15 is a 6.8 kb human islet-specific transcript 
without coding potential located on chromosome 20, in a region upstream of the essential islet 
transcription factor NKX2.2 (221). Interestingly, inhibition of HI-LNC15 in the human β-cell line 
EndoC-βH1 resulted in gene expression changes correlating to those observed in response of 
NKX2.2 knockdown, suggesting that HI-LNC15 and NKX2.2 are part of a common regulatory 
network (8). The sequence of HI-LNC15 is relatively well conserved in mammals and was named 
βlinc1 (β-cell long intergenic noncoding RNA 1) in mice because of its specific expression in β-
cells (13). The mouse βlinc1 locus spans 8 kb and is located on chromosome 2 in a gene desert 
region between Nkx2.2 and Pax1. βlinc1 is expressed at relatively low levels and is mainly nuclear. 
To investigate the functional role of βlinc1, Arnes and colleagues generated a whole-body knockout 
mice (13). Consistent with its islet-specific expression profile, e15.5 and neonate βlinc1-null mice 
displayed a 50% reduction in β-cell mass without other major changes in pancreas morphology. At 
adult age, βlinc1-null mice showed elevated blood insulin levels under basal glucose concentration 
and were both glucose- and insulin-intolerant. Mechanistically, the deletion of βlinc1 led to a 
dysregulation of several genes involved in the specification of endocrine progenitors (including 
NeuroD1 and NeuroG3), in the maturation (including MafA, MafB, Nkx2.2, Nkx 6.2 and Pax6) and 
the function of the β-cells (including Ins1, Ins2, Slc2a2 and Slc30a8). To distinguish the effects 
due to impaired pancreas development to those linked to βlinc1 deletion at adult age, the phenotype 
of the heterozygous mice was also investigated (13). Heterogeneous βlinc1+/- mice did not show 
any defect in islet development or glucose homeostasis but some genes were dysregulated in E15.5 
pancreas of mice lacking one copy of βlinc1, as for βlinc1-null mice. Importantly, five of the top 
10 most dysregulated genes in βlinc1+/− mice were located in the genomic vicinity of the lncRNA, 
suggesting that βlinc1 may coordinate β-cell gene expression through the structural organization 
of the chromatin (13).  
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LncRNAs PLUTO (HI-LNC71) and HI-LNC78  
Akerman and colleagues investigated the implication of several lncRNAs enriched in pancreatic β-
cells in the regulation of gene expression by inhibiting their level in the human EndoC-βH1 cell 
line (8). Among them, HI-LNC71 was found to be the most downregulated in islets of T2D or IGT 
donors compared to controls. This nuclear-enriched transcript is produced from a promoter located 
~3 kb upstream of PDX1 and was therefore named PLUTO for “PDX1 Locus Upstream 
Transcript”. Downregulation of PLUTO in primary human islets or in EndoC-βH1 cells reduced 
PDX1 expression, which resulted from an impaired three dimensional contact between the PDX1 
promoter and its enhancer cluster (8) (Fig. 6A). Moreover, inhibition of the mouse orthologue Pluto 
in the β-cell line MIN6 led to a decrease in Pdx1 expression suggesting that the mode of action of 
PLUTO is conserved in mammals. Functional assays in EndoC-βH1 cells showed that reduction of 
PLUTO expression lead to diminished insulin content and a consequent impairment in insulin 
secretion under stimulatory conditions (8).  
 In the same study, knockdown of nine other β-cell lncRNAs caused a dysregulation, by cis- 
or trans-regulatory mechanisms, of several genes (8). For example, inhibition of HI-LNC78 and 
HI-LNC15 resulted in gene expression changes correlating closely to the ones observed in response 
the knockdown of HNF1A and MAFB, and NKX2.2, respectively. Further analysis suggested that 
a group of β-specific lncRNAs and transcription factors are part of common regulatory 
transcriptional networks that target clusters of pancreatic islet enhancers (8). In addition, the 
expression of HI-LNC78 was found to be regulated by glucose in human islets (221) and 
downregulation of this lncRNA in EndoC-βH1 cells led to a reduction in insulin content and 
defective insulin release (8). Finally, HI-LNC78 orthologues were found in mouse (Tunar) and 
zebrafish (megamind/linc-birc6) (8). 
 
MEG3  
The lncRNA MEG3 (Maternally Expressed Gene 3) is encoded from an imprinted gene transcribed 
from the maternal allele that resides on human chromosome 14 and mouse chromosome 12 (218). 
Of interest, MEG3 gene is part of the DLK1-MEG3 locus that codes for snoRNAs, the non-coding 
genes MEG8 and anti-sense RLT1, the protein-coding genes DLK1, RTL1 and DIO3 and a cluster 
of miRNAs (138). The epigenetic and transcriptional regulation of the ubiquitously expressed 
lncRNA MEG3 are well-conserved between human and mouse. In humans, decreased in MEG3 
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expression has been associated with several cancers (355). In mouse, Meg3 was found to be 
differentially expressed during embryonic development and deletion of this gene caused diverse 
growth and survival defects (53).  
 The expression and the functional role of MEG3/Meg3 were also studied in human and 
mouse islets. Interestingly, MEG3 was found to be downregulated in islets of T2D donors (138) 
and in islets of both T1D (NOD) and T2D (db/db) mouse models compared to aged-matched non-
diabetic Balb/c mice (326, 343). However, these results will need to be reproduced using the 
appropriate SCID and db/+ aged-matched control mice. The exact mechanism controlling MEG3 
expression remains to be uncovered. In mouse, Meg3 is enriched in islets compared to exocrine 
pancreas and to some other tissues and is modulated by glucose (343). In human, reduction of 
MEG3 expression observed in diabetic donors could not be reproduced by incubating control islets 
in vitro with high glucose concentration, but the decrease appeared to be related to the methylation 
status of the MEG3 promoter (138). MEG3 promoter methylation was also associated with the 
enrichment of this lncRNA in FACS-purified human β-cells versus α-cells. More precisely, the 
MEG3 promoter is bivalently marked by the activating histone H3 lysine 4 trimethylation 
(H3K4me3) and the repressive lysine 27 trimethylation (H3K27me3) modifications in glucagon-
secreting cells, while it is almost only marked by activating H3K4me3 in insulin-secreting cells 
(138).  
 To investigate the functional role of this lncRNA, a siRNA directed against Meg3 (siMeg3) 
was injected into the tail vein of Balb/c female mice resulting in about 50% downregulation of 
Meg3 in islets (326, 343). Mice that received siMeg3 showed an impaired glucose tolerance and a 
reduction in serum insulin levels following an intra-peritoneal glucose tolerance test (IPGTT). In 
vitro, inhibition of Meg3 expression in MIN6 cells favored apoptosis, reduced Ins2 expression and 
impaired insulin synthesis and secretion (343). Further studies performed in MIN6 cells and/or 
mouse islets showed that Meg3 is mainly localized in the nucleus where it interacts with the 
methyltransferase EZH2 which is responsible for the trimethylation of H3K27 at Rad21, Smc3, and 
Sin3a promoters. These 3 transcriptional repressors were found to directly interact with MafA 
promotor (326). Consequently, downregulation of lncRNA Meg3 resulted in the loss of EZH2 
binding and H3K27 trimethylation occupancy of Rad21, Smc3, and Sin3a promoters, leading to an 
increase in the levels of these transcription factors and concomitant decrease in MafA expression 
which negatively impact insulin synthesis and secretion (326). The islets of siMeg3 injected mice 
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and of NOD and db/db mice showed reduced levels of Meg3, elevation of Rad21, Smc3 and Sin3a 
expression and altered level of MAFA at both mRNA and protein levels (Fig. 6B) (326, 343). 
Taken together, these results suggest that the lncRNA Meg3 regulates MafA expression, and insulin 
production and secretion. However, since intravenous injection of a siRNA in mice cannot be 
directed specifically to β-cells and that downregulation of a nuclear lncRNA is very hard to achieve 
using siRNA, the generation of a transgenic model is required to confirm the role of Meg3 in the 
regulation of insulin synthesis and secretion.   
Circular RNAs 
Circular RNAs (circRNAs) are covalently closed RNAs initially identified in plant viroids and later 
in eukaryotic cells. Eukaryotic circRNAs can be produced from the sense or antisense sequences 
of protein-coding genes or from ncRNAs. Furthermore, one or more circRNAs isoforms composed 
of intronic and/or exonic sequences can be generated from a parent gene. Circular intronic RNAs 
derive from introns linearly spliced from pre-mRNAs and are typically circularized by 2’-5’ 
junctions at the 5’ nucleotide and a branchpoint nucleotide near the 3’ end of the intron. These 
branched circRNAs termed lariats (circular introns with a linear 3’ tail) can be debranched (i.e. 
linearized) and degraded, or evade debranching and lose their 3’tail, thus becoming stable circular 
transcripts. In contrast, circular exonic and exonic-intronic RNAs can be formed by backsplicing 
of pre-mRNAs, a process in which an upstream 3’ splice site is joined to a downstream 5’ splice 
site leading to the generation of circular transcripts with 3’-5’ junctions (Fig. 7). The median length 
of circRNAs is 547 nucleotides, although some can consist of less than a hundred or up to thousands 
of nucleotides. CircRNAs are neither capped nor polyadenylated (in contrast to linear mRNAs) and 
are resistant to exoribonuclease degradation. Moreover, the lifespan of circRNAs can be longer 
(19-48 h) than that of some linear mRNAs (4-9 h). Once produced, circRNAs can remain in the 
nucleus or be exported to the cytoplasm (114, 160, 170).  
circRNAs and pancreatic islets 
It is estimated that there are over 100’000 circRNAs in human cells. Some of them are conserved 
in other species, are present in particular cell types, and modulate mRNA transcription, splicing, 
and translation, thus affecting diverse cellular processes (114, 160, 170). Likewise, human islet 
cells can produce between 3,441 and 10,374 distinct circRNAs, and around 500 of them are 
conserved in mouse islets (145, 300). Moreover, 36 circRNAs derived from 30 parent genes are 
26 
 
more or less abundant in β-cells compared with α-cells, and about 400 circRNAs are generated 
particularly in one or the other islet cell type. Of these, seven circRNAs are highly selective for α-
cells and one for β-cells. They originate from the most enriched and selectively expressed genes in 
each cell type, i.e. FAP, SYTL5, PTPRT, STK32B, and BVES in α-cells, and TGFBR3 in β-cells (2, 
145). However, their biological role in islet cells remains to be elucidated. Actually, the islet 
function of only three circRNAs has been published (summarized in Table 1). These are circAFF1, 
ciRS-7/Cdr1as, and circHIPK3, which originate from exonic sequences of the genes Aff1, Cdr1, 
and Hipk3, respectively. Modulation of their levels in the mouse β-cell line MIN6 or in rodent islet 
cells revealed that they contribute to the regulation of β-cell insulin secretion and/or mass (300, 
340). Indeed, circAFF1 deficiency enhances cell apoptosis, although it has no effect on β-cell 
proliferation or glucose-stimulated insulin secretion (300). Instead, ciRS-7/Cdr1as overexpression 
increases insulin release in response to glucose (340), while its silencing appears to decrease 
glucose-induced insulin secretion. Moreover, ciRS-7/Cdr1as knockdown reduces β-cell 
proliferation stimulated by prolactin, although it does not affect apoptosis (300). In contrast, low 
levels of circHIPK3 promote apoptosis but reduce prolactin-stimulated β-cell proliferation and 
glucose-induced insulin release (300). CiRS-7 and circHIPK3 act as miRNA sponges, thus 
blocking the action of the bound miRNAs, which results in augmented levels of the corresponding 
miRNA target genes. CiRS-7 binds miR-7 while circHIPK3 contains binding sites for miR-29b-
3p, miR-30, miR-124-3p, and miR-338-3p. Sponging of these miRNAs can thus contribute to the 
upregulation of genes implicated in islet differentiation and in β-cell insulin secretion and mass 
(300, 340). 
The use of bioinformatic tools for analysis and target prediction of ncRNAs 
A large panel of specific bioinformatic tools have been developed to identify the different classes 
of ncRNAs and to predict their potential targets. These tools not only permitted to generate 
comprehensive lists of ncRNAs expressed in mammalian cells but have also be instrumental for 
the definition of their possible mode of action (summarized in Table 2).  
miRNAs 
miRNAs are pivotal factors in defining the specificity and sensitivity of post-transcriptional gene 
silencing. Thus, great efforts have been made to discover new miRNAs, to identify their targets 
and further characterize their functions. The conventional techniques used for the discovery of new 
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miRNAs include cloning, northern blotting, microarray and in situ hybridization even when little 
or no genomic information is available. However, it is not possible to explore all the complexity 
and diversity of miRNAs empirically with biological methods. Fortunately, a variety of 
computational algorithms are available to identify and validate new miRNAs. Early bioinformatic 
methods (165, 186) predicted putative miRNAs in genome sequences based on structural features, 
like hairpin and minimal folding free energy, and sequence conservation with known miRNAs. 
However, these tools essentially focus on evolutionarily conserved miRNAs and have limitations 
for the discovery of novel miRNAs. Machine-learning algorithms have subsequently been devised 
to predict novel miRNAs (summarized in Table 2) (91, 117, 135, 230, 240, 241, 307, 345). 
Previously validated miRNAs were used to train the learning processes to discriminate between 
true predictions and false positives. With the advance of next-generation sequencing (NGS), other 
tools have been developed to predict miRNAs from NGS data (81, 82, 109, 110, 128). Once 
predicted, experimental techniques are used to validate the predictions. In recent years, biological 
and bioinformatic approaches have enabled the discovery of thousands of miRNAs that are now 
documented in the miRbase (157), the primary online repository of miRNA sequences and 
annotation. The latest miRbase (release 22) contains miRNA sequences from 271 organisms, for a 
total of 38’589 hairpin precursors and 48’860 mature miRNAs. 
The next challenge of the miRNA field was the characterization of the biological function of 
the identified miRNAs. Additional and more sophisticated bioinformatic tools were therefore 
required.  The growing understanding of miRNA properties has significantly accelerated the 
development of the bioinformatics tools used for miRNA-target prediction (summarized in Table 
2) (3, 66, 147, 161, 168, 190). For example, the latest version of TargetScan (3) (v7) uses an 
improved model (the context++ model) which considers site type and 14 other features, and 
performs significantly better than existing models. In most cases, miRNA-target prediction 
algorithms were developed based on a set of canonical rules for miRNA-target interactions. 
However, there is substantial evidence for exceptions to these rules, including non-canonical 
bindings that lack obvious seed pairing and contain multiple mismatches, bulges, and wobbles, 
highlighting the complexity in predicting miRNA targets. To help the identification of direct 
miRNA targets, some biochemical approaches have been developed. The most commonly used 
methods are high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
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(HITS-CLIP) (330) and crosslinking, ligation, and sequencing of hybrids (CLASH) (112), 
providing an extensive insight into the miRNA-binding sites. 
piRNAs 
Identification of new piRNAs can be performed by immunoprecipitation of PIWI proteins followed 
by RNA sequencing (175, 235, 244, 328). However, using experimental methods alone is 
laborious, expensive, and not sensitive enough to detect piRNAs expressed at very low level or 
only in certain tissues. With the advancement of deep RNA sequencing, computational methods 
provided an alternative approach for de novo annotation of piRNAs (Table 2).  However, these 
algorithms which are based on general properties from validated piRNAs must be trained to predict 
novel piRNAs. The first algorithm to identify piRNAs was based on  a position-specific method 
that classified the sites along the genome susceptible to generate piRNAs starting with a uridine at 
their 5′ ends (26). Zhang et al. developed a model called piRNA predictor by combining the k-mer 
scheme and support vector machine (SVM) (350). Subsequently, Wang et al. proposed a different 
model for predicting piRNAs by using the transposon interaction and SVM (323). Recently, three 
more papers were published for identifying piRNAs (summarized in Table 2). One was developed 
based on sequential and physicochemical features of piRNA (196), another  developed a genetic 
algorithm-based weighted ensemble method for predicting transposon-derived piRNAs (181) and 
the last one, named 2L-piRNA, was a two-layer ensemble classifier for identifying PIWI-
interacting RNAs and their function (188). 
Identification of piRNA targets has proven to be rather difficult due to limited knowledge in the 
field. Zhang et al. recently proposed piRNA targeting rules explaining how these ncRNAs can find 
mRNA targets in Caenorhabditis elegans (347). Additionally, crosslinking, ligation, and 
sequencing of hybrids (CLASH) approaches have been applied to the PIWI Argonaute in C. 
elegans, which permitted to identify endogenous interactions between piRNAs and target RNAs in 
vivo (287). Both piRNA targeting rules and PIWI CLASH data were used to construct tools pirScan 
(337) and piRTarBase (336) to allow researchers explore how piRNAs recognize the target sites 
and exert their regulatory effects (Table 2). These computational tools may be utilized to identify 
piRNAs and their targets, and thereby unravel the contribution of piRNAs in the control of β-cell 
function under normal or pathophysiological conditions. 
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tRNA-derived fragments 
In recent years, the development of high-throughput small RNA sequencing approaches 
enabled the detection of small RNAs at unprecedented depth. However, many problems associated 
with the identification of tRFs have been noted. First, sequencing biases may occur due to tRNA 
structure and the presence of post-transcriptionally modified residues, which block reverse 
transcription (51). Second, the presence of tRNA isodecoders that share the same amino acid 
sequence in different genomic locations prevents the determination of the exact source of tRFs 
(191). Third, identifying the actual tRFs can be challenging due to difficulties in discriminating 
tRFs from random degradation fragments in a large pool of sequenced small RNAs (354). Certain 
experimental methods have been developed to overcome some of these biases, including artificial 
removal of methylated bases on tRNAs (DMtRNA-Seq and ARM-Seq) (51, 353). In addition, 
several tools have been developed to improve tRNA-Seq bioinformatics analyses (Table 2). For 
instance, the sequence-centric based tool MINTmap (191) catalogs both raw and normalized 
abundances of tRFs using published small RNA-seq data of human tissues under various 
physiological and pathological conditions. The labeling scheme of MINTmap can unambiguously 
calculate and report both raw and normalized abundances for the discovered tRFs. Another freely 
available prediction tool tRF2Cancer (354) has introduced the binomial test to evaluate whether 
reads from a small RNA-seq data set represent tRFs or degraded fragments and evaluate their 
expression in multiple cancers.  
As discussed previously, tRFs have been proposed to be involved in various cellular processes. 
Several computational tools and software have been used to predict the potential targets of tRFs. 
RNAhybrid software (161) has been used to find pairing sites for 3’ETSleuZ with the small 
regulatory RNAs RyhB and RybB, suggesting that tRFs may function as sponges for small RNAs 
to prevent transcriptional noise (167). TargetScan has identified binding sites for a tRFs CU1276, 
possessing characteristics of a miRNA, and predicted its target gene RPA1, an essential gene 
involved in proliferation and DNA damage response (211). Blat has also been utilized to predict 
potential target sites of sperm derived tRFs in mouse genome (40). However, the number of 
validated tRF targets is still relatively small and inadequate to provide an un-biased assessment of 
the binding patterns. In addition, the short length of tRFs limits the sensitivity of detection using 
most statistical techniques. Given these limitations of computational predictions, experiments may 
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be complemented with pull-down experiments using either biotinylated tRFs or candidate target 
proteins as baits (167).  
lncRNAs 
Recent advances in RNA-sequencing technologies led to the discovery of thousands of 
previously unannotated lncRNAs. Generally, lncRNA analysis is a two-layer process, in which the 
first consists in transcript sequencing and assembly, and the second in building a stringent selection 
pipeline to systemically identify the lncRNAs. This pipeline aims at removing known non-lncRNA 
transcripts, unreliable lowly expressed transcripts or with protein-coding potential. Additional 
methods such as quantitative reverse-transcription PCR, 5’ and 3’ rapid amplification of cDNA 
ends (RACE), 5’ capture sequencing (cap-analysis gene expression, CAGE) and 3’ 
Polyadenylation signals (PAS-Seq) can be useful to confirm the ends and isoform structures of 
specific transcripts. 
 Circular RNAs  
Information about the circRNAs detected so far in human and other species can be found in 
annotation databases such as circBase (92). These predicted circRNAs have been identified in RNA 
sequencing data from ribosomal RNA-depleted libraries or from circRNA-enriched libraries 
treated with the exoribonuclease RNase R and depleted of ribosomal RNA. CircRNAs are 
identified using algorithms that detect reads spanning their unique inverted or backsplice junction 
(summarized in Table 2) (42, 89, 215, 297, 303, 324, 331, 344, 349) and reviewed in (111). Their 
sensitivity (number of backsplice-spanning reads) and specificity (lack of false positives) are 
nevertheless different. Hence, it is advised to use at least two prediction algorithms to obtain a more 
accurate annotation of circRNAs.  
Regulation of islet differentiation, functional maturation and ageing  
Pancreatic islet development and β-cell differentiation 
Pancreas development is a complex and tightly regulated process that has been characterized in 
detail in mice but is less well defined in human because of the limited access to human fetal 
specimen. In brief, the pancreas develops from the primitive gut by formation of dorsal and ventral 
buds (mouse E9-10) at the junction of the foregut and the midgut endoderm. Between mouse E12.5 
and E16.5, these pancreatic buds grow and undergo branching morphogenesis. The ventral bud 
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then rotates and fuses with the dorsal bud (E15.5-16.5), forming the definitive pancreas. Of note, 
the ventral bud will become the pancreas head and the main pancreatic duct while the dorsal bud 
will form the tail and the body of the pancreas, and the accessory pancreatic duct. Throughout this 
process, a tight spatio-temporal control of the expression of several transcription factors (including 
Pdx1, Ngn3, NeuroD1, Nkx2.2, Nkx6.1, Pax6, Isl1) is required for the formation and maturation of 
all endocrine and exocrine cell lineages (48). Growing evidence suggest that ncRNAs are also 
important regulators of pancreas and β-cell development (reviewed in (209, 333)).  
miRNAs 
Evidence for a key role of miRNAs for proper pancreas and β-cell development has been obtained 
by the downregulation of the miRNA processing enzyme Dicer1 in different mouse models. 
Conditional deletion of Dicer1 in early pancreatic lineage (E9.5) using Pdx-Cre mice led to 
pancreas agenesis and a strong reduction in various pancreatic endocrine cell types, including β-, 
α-, δ- and PP-cells. Pdx-Cre Dicer KO mice survived until birth but died few days after (197). 
Deletion of Dicer1 specifically in pancreatic endocrine progenitor cells (E12.5) in Ngn3-Cre Dicer 
mice did not affect endocrine cell lineages but caused the production of abnormal hormone levels 
after birth leading to chronic hyperglycemia and diabetes onset by the age of 2 weeks (140). By 
inspecting the endocrine pancreas, the authors observed an altered islet architecture, reduced β-cell 
mass and decreased insulin expression and content (140).  
To address the importance of the miRNA network in β-cell development independently 
from the differentiation of pancreatic progenitor cells, Dicer1 was conditionally deleted under the 
control of the rat insulin promoter 1 (RIP1) or 2 (RIP2) (E15.5) (137, 197, 203, 214). No fetal or 
neonatal β-cell differentiation defects were reported in RIP1-Cre Dicer1-null mice. However, these 
animals showed a reduced β-cell mass, impaired islet number, size and organization, and decreased 
insulin expression by 12 weeks of age. Consequently, these mice displayed diminished insulin 
release in response to glucose and gradually became glucose intolerant and overtly diabetic by 25 
weeks of age (137). Two independent studies investigated the effect of Dicer1 deletion using RIP2-
Cre mice. Similar to the phenotype observed for RIP1-Cre Dicer1-null mice, Mandelbaum et al. 
reported that RIP2-Cre Dicer1-null mice have a reduced β-cell mass and impaired insulin synthesis 
and, consequently, develop fasted and fed hyperglycemia and glucose intolerance by 1-2 months 
of age. In contrast, Lynn and colleagues did not observe any islet morphological changes in 8-
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month-old null mice (197). This discrepancy might be explained by the fact that not all β-cells 
undergo Cre recombination. Overtime, Cre-positive cells may be progressively lost and replaced 
by wild-type Cre-negative β-cells (203). Therefore, the phenotype observed in young animals was 
progressively reversed by the age of 8-10 months (203).  
Finally, to study the effect of Dicer1 deletion more specifically in adult β-cells, Melkman-
Zehavi and colleagues developed a tamoxifen-inducible RIP-Cre Dicer1 mice that showed a 50% 
reduction in Dicer levels in β-cells with a concomitant reduction of miRNA abundance 2 weeks 
after Tamoxifen injection (214). Pancreatic insulin content, and Ins1 and Ins2 expression were 
reduced in Tamoxifen-treated mice (214). Moreover, these mice displayed lower plasma insulin 
levels, impaired insulin release in response to glucose, and became glucose intolerant and 
hyperglycemic in both fasted and fed state. Overall, these studies underline the critical role played 
by DICER 1 and the associated miRNA network in the regulation of pancreas development, β-cell 
mass and function.  
The role of specific miRNAs in pancreas development has also been investigated (reviewed 
in (209, 333)). In human, the expression of two islet-enriched miRNAs, miR-7 and miR-375, were 
found to be increased during pancreatic endocrine cell development and differentiation (49, 133). 
Similar results were obtained for mouse pancreas development (158, 159, 234). Both miR-7 and 
miR-375 expression were blunted in Ngn3-null mice that lack hormone-producing cells (158), 
suggesting an involvement of these miRNAs in endocrine cell development. Several research 
groups attempted to define the role played by miR-7 during β-cell differentiation using different 
animal models (158, 172, 234). Kredo-Russo and colleagues found that miR-7 reduces insulin 
expression by limiting PAX6 levels in β-cells both ex vivo, in E12.5 pancreatic buds transfected 
with miR-7 inhibitors or mimics, and in vivo in E15.5 pancreata of Pdx1-Cre mir-7 transgenic mice 
(158). The authors found also that miR-7 inhibits glucagon expression and favors the appearance 
of ghrelin-positive cells (158). Latreille and colleagues did not observe defects in islet architecture 
or in β-cell mass in RIP-Cre mir-7 transgenic mice at adult age (172). However, they reported a 
reduction in Ins1 and Ins2 levels in the islets of transgenic mice overexpressing mir-7 and an 
upregulation of the insulin levels in mir-7 null mice, with a consequent impact on β-cell function. 
The role of miR-375 in β-cell development remains at present unclear. In an earlier study, injection 
of miR-375 inhibitors in one-cell-stage zebrafish embryo led to aberrant islet formation (152).  
However whole-body mir-375 null mice did not show any major defect in islet α- and β-cell 
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number, or hormone expression in the first two weeks of life. Disrupted islet architecture could 
only be observed after 3 weeks of age, suggesting that in mice, miR-375 is not essential for β-cell 
formation but is required for maturation and function (255).  
 Of course, this type of studies cannot be performed in human. However, the role of 
miRNAs has been investigated by following the differentiation process of human embryonic stem 
cells (hESCs) into a β-cell-like phenotype or during the generation of pluripotent stem cell (hiPSC)-
derived insulin-producing cells (80, 192). Three miRNAs (miR-7, miR-375 and miR-373) were 
found to be highly upregulated in the early stages of hESC differentiation into the definitive 
endoderm, while miR-15a/b and miR-16a were mainly increased during endocrine induction. 
Finally, miR-29b and miR-148 reached a peak in the late stage of endocrine proliferation (192). 
Increased levels of miR-375 and miR-7 favored the differentiation of hESCs into insulin-
expressing cells and/or exacerbated insulin secretion in response to glucose (48, 80). The rise of 
miR-7 during early hESC differentiation coincides with an increase in the expression of pancreatic 
markers, including FOXA2, PDX1, and insulin. In contrast, blockade of miR-7 partially inhibited 
glucose- and KCl-induced insulin secretion. Several other miRNAs are likely to play a role in β-
cell formation since they regulate the level of important transcription factors, including Ngn3, 
NeuroD1 and Foxa2 (reviewed in (80, 146, 209)).  
snoRNAs 
Beside miRNAs, other small ncRNAs may also be of importance for β-cell development and 
differentiation. Burnett and colleagues investigated the impact Snord116 paternal allele deletion 
(Snord116p-/m+ mice) on endocrine pancreas development (30). Snord116 is a gene cluster 
containing around 30 C/D box snoRNAs that are 85% homologous to each other. SNOD116 
snoRNAs are localized into nucleoli but are called “orphan” since they do not have known rRNA 
targets. Snord116p-/m+ mice displayed a reduced islet size at both neonatal and adult age. 
Throughout life, the islets of Snord116p-/m+ mice contained a number of β-cells comparable to WT 
animals but the proportion of δ- and α-cells was increased and decreased, respectively. Also, 
Snord116p-/m+ islet cells were characterized by a more polyhormonal profile during the neonatal 
life, and a lower expression of endocrine pancreas progenitors such as Pdx1, Pax6, and Nkx6.1, 
during adulthood (30). Therefore, snoRNAs produced from the Snord116 locus may play an 
important role in islet cell lineage specification.       
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lncRNAs  
Different studies suggest that lncRNAs are required for proper β-cell development (reviewed in 
(333)). As mentioned above, βlinc1-null mice display a 50% reduction in β-cell mass in e15.5 
embryos and in newborn without major impacts on pancreas morphology (13). PLUTO may also 
be involved since it regulates the levels of PDX1 (8), a transcription factor known to be crucial for 
pancreas development and β-cell identity (134, 237). Moran and colleagues investigated the 
involvement of lncRNAs  in human β-cell development by analyzing the expression of 13 lncRNAs 
(10 intergenic and 3 antisense) in dissected Carnegie stage 17–19 human embryonic pancreas, a 
progenitor stage that shows scarce signs of cytodifferentiation (221). Of these 13 transcripts, 12 
were silent or expressed at very low level in pancreatic progenitors but were readily detectable in 
adult islets. The expression of most of them were also activated only at the final in vivo maturation 
step of the human embryonic stem (hES) cells (13). Finally, two lncRNAs, HI-LNC78 and HI-
LNC80, were upregulated in human islets incubated for 72h with glucose concentrations (221). A 
major fraction of the lncRNAs investigated in this study were found to have orthologues in mouse 
islets that were also displaying expression changes during pancreas development, islet maturation, 
in response to glucose and/or in islets of obese and diabetic db/db mice (221). This suggests that 
the function of islet-specific lncRNAs may be conserved among mammals Taken together, these 
results suggest a highly dynamic and cell-specific regulation of islet lncRNAs potentially 
contributing to β-cell development.  
Functional maturation of β-cells     
 miRNAs 
The acquisition of a fully functional phenotype requires a reprogramming of the gene networks 
expressed in newly generated islet cells that occurs during the neonatal period. MiRNAs have been 
highlighted as import players in this process and contribute to disallow the expression of more than 
60 ubiquitously expressed genes that negatively impact on β-cell identity and function and need to 
be specifically silenced in fully differentiated β-cells (143, 179, 209). Indeed, β-cell-specific 
inactivation of the miRNA-processing enzyme Dicer at adulthood leads to the up-regulation of 
several β-cell disallowed genes, resulting in reduced insulin content, decreased β-cell mass and 
IGT (208). In line with these findings, miR-29a and b, expressed at elevated levels in mature β-
cells directly target the lactate/pyruvate transporter Mct1 (monocarboxylate transporter 1) (256). 
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Repression of Mct1 avoids the induction of insulin secretion in response to a rise in lactate 
generated during physical activities (258). Moreover, direct inhibition of MCT1 by miR-495 in 
human embryonic stem cells transplanted under the kidney capsule improved glucose tolerance of 
obese mice fed on a HFD (185).  
Changes in the level of several other miRNAs have also been proposed to contribute to 
postnatal β-cell maturation and to the acquisition and maintenance of fully mature and functional 
β-cells (124). For example, miR-17-5p and miR-181a were found to regulate the expression of 
several genes involved in glucose metabolism, insulin secretion and proliferation (124). The 
nutritional switch occurring at weaning from fat-rich maternal milk to a carbohydrate-rich diet 
drives β-cell maturation (124, 301) and triggers major changes in the miRNA profile that enable 
the coupling of glucose metabolism with insulin secretion (124). Nutrition-driven islet miRNA 
changes affects also the control of circadian rhythms during postnatal β-cell maturation (125). 
Indeed, the transcriptional oscillations of several core-clock genes over 24 hours observed in 
freshly isolated adult rat islets are not detected in the islets of P10 rats, suggesting that the circadian 
clock is not yet fully operational in newborn animals. Indeed, P10 islet cells synchronized in vitro 
displayed rhythmic oscillations of Bmal1–luc reporter but differed significantly from those of their 
adult counterparts. Among the miRNAs differentially expressed during neonatal β-cell maturation, 
miR-17-3p and miR-29b-3p were shown to directly regulate the expression of clock and per3, 
respectively. These findings point to a role for miRNAs driving β-cell maturation in the regulation 
of adult circadian gene expression (125). However, further investigations are needed to elucidate 
the mechanisms involved in the initiation of the circadian clock in the developing islets that are 
likely to result from the cooperative action of multiple miRNAs and of other factors.  
Dumortier et al. discovered a perturbation of the pancreatic miRNA expression profile in 
the offspring of rat dams fed a low-protein (LP) diet during gestation and lactation (60). These 
offspring are more prone to develop metabolic diseases, including diabetes, later in life compared 
to offspring of dams fed on normal diet (76, 206). In particular, they observed a rise in the level of 
miR-375 in fetal pancreas that persisted in the islets of adult (3-month-old) rats born from mothers 
maintained on LP diet. The authors proposed an inhibitory role for miR-375 in embryonic and 
postnatal β-cell mass expansion and in insulin secretion, contributing to the establishment of the 
phenotype observed in the offspring of rat dams kept on LP diet during pregnancy and lactation 
(60). An independent study, reported that insulin secretion and content in adult mouse islets from 
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the offspring of LP-exposed mothers can be improved and returned to normal by preventing the 
rise of miR-199a-3p, miR-342 and miR-375 and restoring the mTOR signaling pathway. Moreover, 
transient induction of mTORC1 signaling in vivo during embryonic life until birth, improved 
glucose tolerance in adult progeny of mothers fed a LP diet (9). 
lncRNAs 
The role of lncRNAs in neonatal β-cell maturation has been investigated by performing a global 
profiling in islets of newborn (P10) and adult rats (276). This led to the identification of over 2000 
differentially expressed lncRNAs. H19, a maternally imprinted lncRNA generated from the Igf2 
locus (346) was among the most downregulated transcripts during neonatal β-cell maturation. This 
lncRNA was previously reported to be involved in mouse embryonic development and postnatal 
growth (88) and to sustain cancer cell proliferation (174). H19 expression in neonatal islets appears 
to be controlled by the transcription factor E2F1, an important regulator of β-cell survival and 
proliferation (75). H19 was found to promote β-cell proliferation by sponging miRNAs, including 
members of the let-7 family, and thus favoring the activation of the PI3K/AKT pathway (Fig. 6C). 
Interestingly, H19 expression was upregulated in islets of different obese mouse models 
characterized by insulin resistance and to be downregulated in islets of the offspring of rat dams 
fed on a LP diet that are prone to develop metabolic diseases later in life (276). Thus, appropriate 
expression of H19, and probably of other lncRNAs, appears to be required for β-cell mass 
expansion.      
β-cell mass expansion during obesity and gestation 
During pregnancy and obesity, reduced insulin sensitivity of target tissues results in increased 
insulin needs. Pancreatic β-cells can respond to the rise in the metabolic demand by increasing their 
number, size, and by augmenting their secretory activity. If this compensatory process fails, 
gestational or T2D occurs (Fig. 1).  
miRNAs 
To distinguish the contribution of genetics and obesity on miRNA regulation, Zhao et al. compared 
islet samples of two mouse strains, diabetes resistant C57BL/6 (B6) and diabetes-susceptible 
BTBR mice, with those of their morbidly obese peers, B6-ob/ob and BTBR-ob/ob, respectively 
(351).  The authors identified changes in a subset of obesity-dependent miRNAs in islets of both, 
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B6-ob/ob and BTBR-ob/ob mice compared with their respective lean controls. Interestingly, the 
magnitude of the upregulated miR-132 and -212 was much greater in islets of B6 mice compared 
to BTBR mice whereas miR-204 and miR-7b levels were only modified in response to obesity in 
the islets of BTBR, but not from B6 mice. The strain differences in the islet miRNA profile in 
response to obesity may help understanding the relationship between miRNA regulation and 
diabetes resistance (B6) or susceptibility (BTBR) (351).    
Several miRNAs have been found to be important contributors to successful β-cell 
adaptation to insulin resistance. Latreille et al. observed a strong reduction of miR-7a in islets of 
DIO mice, obese non diabetic ob/ob mice and in human islets exposed to an obesogenic 
environment after transplantation under the kidney capsule of DIO mice (172). MiR-7 expression 
gradually increased in islets of hyperglycemic animal models, suggesting that low levels of this 
miRNA are necessary to achieve a successful β-cell compensation.  
The level of miR-206 is increased in islets, brain and liver of DIO mice. Genetic deletion 
of mir-206 resulted in improved glucose tolerance both in mice fed with chow or high-fat diet. This 
was associated with enhanced insulin secretion and no changes in insulin sensitivity. Islets isolated 
from mir-206-knockout mice displayed higher glucokinase (GCK) mRNA levels and activity. 
Indeed, Gck, a key sensor of β-cell glucose metabolism, was shown to be a direct target miR-206. 
Interestingly, haploinsufficiency of Gck led to insufficient β-cell hyperplasia and failure in β-cell 
mass expansion in response to insulin resistance (308). Altogether, these results strongly suggest 
that miR-206 is vital to achieve successful GCK-dependent β-cell compensation in the context of 
obesity (321). 
Interestingly, miR-132 is highly increased whereas miR-184 is strongly reduced in obese 
leptin-deficient ob/ob mice, as well as in diet-induced obese mice (DIO) and in young (6-week-
old) leptin receptor-deficient db/db mice, which are obese and insulin resistant, but still 
normoglycemic (228, 231, 351). As discussed previously, overexpression of miR-132 promotes β-
cell proliferation, cell survival in response to pro-apoptotic conditions and increases insulin release 
in response to glucose without affecting insulin content (228, 229, 231, 298). Moreover, insulin 
resistant DIO mice treated with an adeno-associated virus (AAV) vector containing miR-132 under 
control of the insulin promoter showed improved glucose homeostasis as a result of increased 
insulin secretion and β-cell proliferation (228). Altogether, these data suggest a positive impact of 
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miR-132 in the control of β-cell function and a potential contribution to β-cell adaptation to obesity. 
Decreased levels of miR-184 can also favor β-cell proliferation and therefore contribute to 
the adaptive metabolic response to counteract diabetes development (231). Studies showing that 
miR-184 levels are reduced in response to high glucose exposure in vitro while they are elevated 
in islets of fasted mice or mice fed a low-sugar diet (305), likely in an AMPK-dependent 
mechanism (207), further suggest that miR-184 depletion plays a central role in the compensatory 
adaptation of β-cell activities in response to an obesogenic environment. This essential role was 
further validated by Tattikota et al., whom enforced the expression of the miRNA in a context of 
obesity by crossing transgenic miR-184 mice with ob/ob mice (306). The β-cell mass of transgenic 
miR-184 ob/ob mice failed to compensate for insulin-resistance and, in contrast to normal ob/ob 
mice, exhibited a reduced islet insulin content, a drop of plasmatic insulin levels and 
hyperglycemia. 
Interestingly, neither the α-cell mass nor the expression of abundant islet miRNAs such as 
miR-375 were affected in these animals. Though, previous reports by Poy et al. demonstrated that 
miR-375 is required for β-cell compensation in obese ob/ob mice (255). Moreover, a study 
conducted by Jacovetti et al., did not detect any changes in the expression of miR-375 and miR-
184 in the islets of pregnant rats (122). Interestingly, miR-338-3p, another miRNA displaying 
expression changes in the islets of obese prediabetic db/db and DIO mice is also decreased in islets 
of pregnant rats. These results further suggest that mechanisms that trigger β-cell compensation 
may differ depending on the physiological (pregnancy) or pathological (obesity) conditions driving 
insulin resistance. It was possible to reproduce the decrease of miR-338-3p by activating the 
cAMP/PKA-dependent pathway which seems to be elicited by the activation of the non-canonical 
estrogen receptor GPR30 during gestation and the glucagon-like peptide 1 receptor during obesity. 
Down-regulation of miR-338-3p did not interfere with the secretory capacity of β-cells but boosted 
their proliferation and promoted their survival under pro-apoptotic conditions. Despite the direct 
targets of the miRNA have still not yet been identified, miR-338-3p inhibition in rat islet cells 
elicited changes in the expression of several genes important for β-cell proliferation and survival 
(122). 
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lncRNAs 
Beside miRNAs, little is known about the role of other ncRNAs in β-cell mass expansion observed 
during pregnancy and/or obesity. To address this question, lncRNA profiling of islets of pregnant 
mice at gestational day 14.5 (compared to non-pregnant mice) was performed and allowed the 
identification of 6 lncRNAs (named lnc01-06) that were dysregulated during pregnancy (293). Of 
them, lnc03 and lnc06 were found to be highly enriched in islets compared to exocrine pancreas 
and other tissues. The increase of lnc03 and lnc04 in pregnancy was mimicked by incubation of 
mouse islets in vitro with the gestational hormone prolactin. Furthermore, downregulation of lnc03 
in MIN6 cells and mouse islets inhibited prolactin induced β-cell proliferation, suggesting the 
involvement for lnc03 in β-cell mass expansion during pregnancy (293).   
Ageing    
β-cell senescence leading to a loss of function and proliferative arrest increases with age and 
represents a risk factor for diabetes development (4, 54). Moreover, β-cell dedifferentiation and 
conversion to non-β pancreatic endocrine cells has been reported following physiological stresses 
such as aging (304). The analysis of the miRNA profile in islets of 3- and 12-month rats led to the 
identification of 69 differentially expressed miRNAs in aged animals. In vitro modulation of age-
related changes of miR-34a (up-regulated) and miR-181a (down-regulated) prevented GLP1- or 
PDGF-induced β-cell proliferation of 3-month rats. These results reproduce the failure of β-cell to 
respond to these mitotic stimuli observed in aged rats (312). MiR-34a directly controls the 
expression of Pdgfra, a disallowed gene that limits the proliferative capacity of adult β-cells (39). 
As discussed here after (see Section titled “Type 1 Diabetes”) miR-34a has been demonstrated to 
affect cell survival and insulin-granule exocytosis (71, 194, 266, 312). The positive correlation of 
miR-34a levels with age in human islet donors suggests an evolutionarily conserved mechanism 
for the regulation of this miRNA (312). 
Deregulation of non-coding RNAs under pathophysiological conditions 
Type 1 Diabetes 
T1D is an auto-immune disorder caused by the selective attack of pancreatic β-cells by the immune 
system leading to the near complete absence of insulin production. The precise mechanisms 
causing the deregulation of the immune system remain to be elucidated, but part of the detrimental 
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effects on β-cell survival is due to the release by the immune cells of pro-inflammatory cytokines, 
including TNFα, IL-1β and IFNγ, and exosomes (64, 100). Unfortunately, patients suffering from 
T1D are diagnosed when more than 90% of the β-cells have already been destroyed, so it is very 
difficult to investigate T1D development in human. Therefore, most of the studies are performed 
in rodent models. The non-obese diabetic (NOD) mice spontaneously develop T1D similarly to 
what observed in human (246) with a progressive infiltration of immune cells around pancreatic 
islets starting at 6-8 weeks of age and a total invasion of the islets by 12-14 weeks of age. About 
80% of female NOD mice develop diabetes by the age of 16-20 weeks. A chemical approach 
consisting in multiple injections of low doses of streptozotocin is frequently used to induce β-cell 
death and mimic T1D development (87). The advantage of this model is that β-cell destruction is 
achieved in all animals within only a few days. However, streptozotocin injection does not mimic 
the autoimmune reaction observed during T1D development.  
miRNAs 
Global miRNA profiling in islets of 4, 8 and 12 weeks-old female NOD mice led to the 
identification several miRNAs dysregulated during T1D development (267). Among them, miR-
29 family members were found to be highly upregulated along disease progression. Interestingly, 
the increase in the expression of miR-29a/b/c could be reproduced by incubating mouse and human 
islets in vitro with pro-inflammatory cytokines (29, 267). To determine the functional impact of 
miR-29 upregulation on β-cells, MIN6 cells and mouse islets were transfected with miRNA 
mimics. This resulted in a rise in apoptosis caused by a direct interaction of the miRNAs with the 
3’UTR of Mcl1. Masking miR-29 binding site on Mcl1 with a protector oligonucleotide prevented 
β-cell death induced by miR-29 or pro-inflammatory cytokines. Moreover, overexpression of miR-
29a/b/c reduced insulin secretion in response to glucose. This was paralleled by a decrease in the 
level of ONECUT2 and a concomitant rise in Granuphilin, a secretory granule protein potently 
inhibiting exocytosis (267). The role of miR-29 was also investigated in mice in which the two 
genomic clusters producing this miRNA family were independently knockdown: mir-29a/b-1 locus 
(KO mir-29a/b) or mir-29b-2/c locus (KO mir-29b/c) (59). Of note, miR-29 family is not solely 
expressed in β-cells but is also highly abundant in liver. Indeed, both KO mir-29a/b-1 and KO mir-
29b/c animals showed increased insulin sensitivity of peripheral tissues and insulin signaling in 
liver. However, KO mir-29b/c animals displayed normal fasting blood glucose and insulin levels, 
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and did not show any glucose intolerance, despite a mild reduction of insulin levels in response to 
an IPGTT. In contrast, mice deficient for mir-29a/b-1 were hyperglycemic and glucose intolerant, 
displayed reduced fasting insulinemia and blunted insulin levels following an IPGTT. Ex vivo, 
insulin content and release in response to glucose in the islets of KO mir-29a/b was normal but 
basal insulin secretion was markedly affected. Onecut2 and Granuphilin were not changed in KO 
animals. However, Mct1, Stx1a and Vamp3 were modulated and increased expression of Sxt1a in 
islets might explain the reduced insulin exocytosis (59). These results are difficult to reconcile with 
those obtained in vitro upon overexpression of miR-29 family members (267). However, since 
insulin sensitivity was also affected in whole body KO animals, generation of transgenic mice with 
a β-cell specific ablation or overexpression of miR-29 family members will be required to fully 
understand the role of miR-29 in the regulation of insulin exocytosis under normal and diabetic 
conditions.   
 The upregulation of three other miRNAs, miR-21a-5p, miR-34a-5p and miR-146a-5p, 
observed in islets of pre-diabetic NOD mice could be mimicked by incubating human islets with 
IL-1β (266). Interestingly, miR-146a-5p expression was found to be controlled by NFkB, a well-
known mediator of cytokine-induced β-cell death. As expected, blockade of miR-146a-5p in MIN6 
cells prevented apoptosis and c-Jun expression induced by IL-1β. At the opposite, overexpression 
of this miRNA favored apoptosis (266). Increased levels of miR-34a-5p cells also promoted 
apoptosis and affected insulin expression, content and secretion in response to glucose. While miR-
34a was previously reported to activate p53 and to decrease β-cell survival (194),  the effect  of 
miR-34a on insulin release was mediated, at least in part, by reduction of VAMP2 and of the 
GTPase Rab3a, two proteins involved in insulin exocytosis (266). Finally, overexpression of miR-
21 blunted glucose-induced insulin release with a concomitant decrease in the expression of 
regulators of insulin secretion, including VAMP2, RAB3 and PCLO (29, 266). Furthermore, some 
reports observed that miR-21 induction promotes β-cell apoptosis by directly targeting the anti-
apoptotic gene Bcl2 (16, 291). Nevertheless, miR-21 involvement in β-cell death is complex and 
controversial since other studies failed to observe an impact on β-cell viability upon miR-21 
overexpression (266). MiR-21 was even suggested to potentially mediate the protective effect of 
NF-κB in mouse β-cells. Indeed, NF-κB prevents insulin-secreting cell death and activates miR-21 
promoter (269). Moreover, inhibition of miR-21 up-regulates the expression, at both mRNA and 
protein levels, of the tumor suppressor PDCD4 in β-TC-6 cell line, and consistently promotes 
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MIN6 cell apoptosis (29, 266, 269). Further investigations are still required to clarify miR-21 
implication on β-cell death in T1D setting. 
Several other miRNAs were dysregulated in response to pro-inflammatory cytokines in 
both human and mouse islets (29, 97, 98, 266). Among them, miR-23a-3p, miR-23b-3p, miR-149-
5p, miR-204 and miR-211-5p were downregulated in human islets and EndoC-βH1 cells treated 
with IL-1β and IFNγ (97, 98). These miRNAs could be part of the mechanisms by which cytokines 
induce β-cell death since decrease in their levels in human β-cells favor apoptosis and the 
expression of the pro-apoptotic genes PUMA and DP5 belonging to Bcl-2 family (97, 98). 
Moreover, co-depletion of miR-211-5p and miR-204 in human EndoC-βH1 cells induced 
expression of ER stress markers including CHOP, ATF3, ATF4 and EIF2A, in a PERK-dependent 
manner. Interestingly, miR-204 and miR-211-5p were reported to directly target, respectively, 
PERK in β-cells (338) and Chop in fibroblast NIH-3T3 cells (44).        
Beside miRNA changes induced by pro-inflammatory conditions, β-cell dysfunction and 
death might also been caused by miRNA transfer from exosomes produced by T cells (see Section 
titled “Extracellular non-coding RNAs”). 
LncRNAs  
To investigate a possible involvement of lncRNAs in T1D development, Motterle et al. performed 
a global profiling of annotated lncRNAs in MIN6 cells exposed to pro-inflammatory cytokines and 
identified more than 650 dysregulated long non-coding transcripts (225). Of them, four lncRNAs 
(lncRNA-1 gm5970, lncRNA-2 AI451557, lncRNA-3 BC002288, lncRNA-4 gm16675) were 
selected for further analysis and their upregulation was confirmed in mouse islets treated with a 
mix of IFNγ, TNFα and IL-1β. Interestingly, the expression of lncRNA-1 -2 and -3 was also 
increased in islets of pre-diabetic female NOD mice during insulitis but not in immunodeficient 
control NOD SCID mice that do not develop diabetes (225), suggesting the involvement of the 
autoimmune reaction in the induction of these lncRNAs. Looking at their functions, these four 
lncRNAs were found to favor apoptosis in both MIN6 and mouse β-cells without affecting insulin 
secretion and content. Mechanistically, overexpression of lncRNA-1 gm5970 promoted cell death 
by inducing NFκB translocation to the nucleus (225). This first study highlight the possible 
involvement of lncRNAs in β-cell death during the immune cell invasion of the pancreatic islets, 
but further studies are needed to fully understand the role of lncRNAs in T1D development.  
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Other non-coding RNAs 
Global profiling for piRNAs, snoRNAs, tRFs, and circRNAs remains to be performed in islets of 
T1D animal models in order to elucidate the involvement of these classes of ncRNAs in the 
development of this disease. So far, only the circRNA circARHGAP12 has been reported to be 
altered in the islets of pre-diabetic NOD mice. However, decreasing its level in MIN6 cells did not 
affect insulin secretion, proliferation, nor apoptosis (300). 
Type 2 Diabetes 
T2D develops when pancreatic β-cells are unable to release enough insulin to compensate for the 
diminished sensitivity of peripheral tissues. The main factors predisposing to T2D are excessive 
caloric intake and sedentary lifestyle combined with genetic susceptibility. In rodents, several 
models exist to study the etiology of this disease. Ob/ob and db/db mice, lacking leptin and the 
leptin receptor, respectively, display massive obesity and hyperinsulinemia with or without chronic 
hyperglycemia according to the genetic background (150, 187). These models are extreme and 
reflect only the condition of a fraction of T2D patients that are overtly obese. Therefore, diet-
induced obesity (DIO) is considered more representative of T2D development in human. In this 
model, mice are fed on a HFD for 2-3 months leading to progressive weight gain, hyperglycemia 
and hyperinsulinemia (248). Interestingly, the ability to compensate for insulin resistance differs 
in each individual mouse and provides a good opportunity to study the mechanisms leading to 
compensation or failure of β-cells (248). Goto–Kakizaki (GK) rats are a model of spontaneous T2D 
development. These rats are non-obese but have a defect in insulin release in response to glucose 
leading to chronic hyperglycemia (253).     
The possibility to obtain human islets for research from pre-diabetic and T2D donors 
increased considerably in recent years, thanks to improvements in pancreatic acquisition, isolation 
methods and delivery systems. The access at these precious biological samples provided 
tremendously helpful information about the molecular mechanisms involved in β-cell dysfunction 
associated with obesogenic environment or diabetes duration in human, giving hope for the use of 
these data in the development of future therapeutic strategies to prevent diabetes. The analysis of 
the miRNA profile of islets obtained from human donors with and without T2D revealed that only 
a fraction of the miRNAs displaying expression changes in the islets of diabetes animal models are 
also dysregulated in the islets of T2D individuals. In contrast, the analysis of islet samples of 
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healthy and diabetic patients led to the identification of new sets of diabetes-associated miRNAs 
previously not detected in animal models. As discussed elsewhere (104), these apparently 
discrepant findings can be explained by multiple factors and will probably apply to other classes 
of ncRNAs. In fact, the experiments carried out in rodents permit to avoid confounding effects such 
as genetic variability, differences linked to diet, T2D treatment, life style, age, gender and others. 
Thus, some of the changes observed in the islets of diabetes animal models may be difficult to 
reproduce in small human cohorts in which the influence of all these confounding factors cannot 
be avoided. In addition, at least part of the differences in  ncRNAs expression detected in diabetes 
animal models are likely to be the consequence of chronically elevated blood glucose levels, a 
condition that is prevented in properly treated T2D patients. On the other hand, some of the 
differences in ncRNA expression associated with T2D in human islets may reflect an unfavorable 
genetic background predisposing to diabetes development or be the consequence of 
pharmacological treatments. Therefore, confirmed by additional studies involving larger human 
cohorts permitting to avoid potential confounding effects, these limitations should be taken into 
account when interpreting the results described below. A better reporting of the characteristics of 
human islets used in the different studies and of the diabetic donor information (when available) 
which are now becoming mandatory for publication in most journals (249, 250) will probably help 
to obtain more reproducible data. 
miRNAs 
Numerous studies conducted in islets isolated from T2D animal models reported changes in 
miRNA expression occurring during disease progression. Many of these studies have already been 
described in previous sections and have been extensively discussed in several other reviews (103, 
104, 169, 209, 239, 329). In this section, we will focus exclusively on data collected from islets of 
human T2D donors or from transgenic and knock-out animal models in which miRNAs levels were 
modulated in attempt to prevent or reverse T2D in vivo. 
To identify dysregulated miRNAs in human islets of T2D donors, two studies performed 
global miRNA profiling by small RNA-seq and RT-qPCR-based array. These studies reported 
elevated expression of miR-187-5p, miR-187-3p, miR-224 and miR-589 in islets of T2D donors, 
while miR-7, miR-369, miR-487a, miR-655 and miR-656 were reduced compared to islets from 
non-diabetic donors (138, 189) . Moreover, Kameswaran et al. observed repression in islets from 
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T2D donors of a cluster of miRNAs generated from the imprinted DLK1-MEG3 locus located on 
chromosome 14q32. Under diabetic conditions, β-cells were proposed to be sensitized to apoptosis, 
through the direct regulation of the pro-apoptotic genes IAPP and TP53INP1, via miR-376a and 
miR-432, two miRNAs generated from the DLK1-MEG3 locus (138). Locke et al. further 
investigated the role of miR-187-3p in the control of β-cell functions (189). Elevated miR-187-3p 
expression negatively correlated with glucose-stimulated insulin secretion in islets from 
normoglycemic donors. Consistently, overexpression of miR-187 in rat islets and INS-1 cells 
resulted in impaired insulin secretion. Moreover, miR-187 was found to inhibit insulin release by 
directly repressing the level of the homeodomain-interacting protein kinase-3 (Hipk3), a known 
regulator of insulin secretion, which is reduced in islets from individuals with T2D (189). 
As described above, miR-7 is down-regulated in islets of obese mouse models (HFD and 
ob/ob) that maintain normoglycemia through compensatory insulin secretion, but is up-regulated 
in islets of db/db mice which develop hyperglycemia and display reduced circulating insulin levels 
due to β-cell dysfunction. Moreover, this miRNA is reduced in GK rats, a non-obese model of T2D 
(69, 172). Consistently, Latreille et al. noticed reduced miR-7a levels in human islets transplanted 
in HFD mice and therefore exposed to an obesogenic environment (172). However, 10 weeks after 
transplantation miR-7a levels rose significantly, demonstrating the anti-correlation of miR-7a 
expression with the diabetogenic state of the mice. The authors observed lower levels of miR-7a in 
obese and nondiabetic subjects, but surprisingly miR-7a expression was also low in islets of 
moderate T2D human samples. This result was explained by the fact that this cohort includes 
patients undergoing a transitory phase of the disease, with β-cells still able to compensate for 
increased insulin needs in response to insulin resistance. Altogether, these observations indicate 
that miR-7 expression negatively correlates with β-cell compensation and preservation of the 
secretory function. Furthermore, transgenic mice overexpressing mir-7a-2 selectively in β-cells 
(Tg7a2) developed diabetes due to impaired insulin secretion and β-cell dedifferentiation (172) as 
discussed in the Section titled “Involvement of miRNAs in the control of β-cell functions”. 
Besides profiling, other miRNAs of interest were measured by qPCR and reported to be 
expressed at different levels in islets of T2D donors. While Kameswaran et al. did not observe a 
differences in miR-184 levels in their cohort (138), Tattikota et al. reported a reduction of miR-184 
in the islets of T2D human subjects consistent with the observations in different animal models of 
obesity and diabetes (231, 306). Indeed, miR-184 appears to positively contribute to compensatory 
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β-cell mass expansion under conditions of obesity in rodents (see Section titled “β-cell mass 
expansion during obesity and gestation”) (231, 305).  
Other reports investigated the role of miR-130a-3p, miR-130b-3p, and miR-152-3p and 
miR-335, initially found to be increased in the islets of diabetic GK rats (69) and, more recently 
discovered to be dysregulated in islets from glucose intolerant (274) or hyperglycemic donors 
(238). Elevated miR-335 levels correlated with altered insulin secretion from islets of human pre-
diabetic donors. Overexpression of miR-335 blunted glucose-induced insulin secretion of human 
EndoC-βH1 cells and of a rat β-cell line by altering insulin-granule exocytosis (274). 
Overexpression of miR-130a-3p, miR-130b-3p, and miR-152-3p individually resulted in decreased 
ATP content and cytosolic ATP/ADP ratios in INS-1 832/13 cells. By altering intracellular ATP 
dynamics, overexpression of these miRNAs also impaired glucose-stimulated insulin secretion and 
insulin biosynthesis. These miRNAs likely negatively regulate ATP-dependent insulin processes 
by reducing the mRNA and protein levels of pyruvate dehydrogenase E1 alpha (PDHA1) and GCK, 
both limiting factors for ATP production (238).  
The expression of miR-124a raises during mouse embryonic pancreatic development (20) 
and is elevated in human pancreatic islets of T2D donors (282). In insulin-secreting MIN6 cells, 
miR-124a was shown to directly regulate the expression of genes involved in insulin granule 
exocytosis (Mtpn) or in glucose sensing (Foxa2). Moreover, in MIN6 cells miR-124 was found to 
negatively regulate insulin biosynthesis and insulin release by inhibiting Foxa2 levels, which in 
turn resulted in diminished of Pdx1, Kir6.2 and Sur1, and by modulating the levels of other 
regulators of insulin exocytosis such as SNAP25, Rab3A, synapsin-1A, Rab27A and Noc2 (20, 
193, 282).     
Dysregulation of miRNA expression in human islets may also be linked to maturity-onset 
diabetes of the young (MODY). A mild rise of miR-802 levels in the islets of diabetic db/db mice 
and a more striking elevation of miR-802 expression in the liver of obese human individuals and 
DIO and db/db mouse models have been associated with changes in insulin sensitivity and Hfn1b 
expression. Moreover, transgenic mice overexpressing mir-802 were glucose intolerant and insulin 
resistant (154). Despite, the mode of action of miR-802 in β-cells has not yet been elucidated, this 
miRNA may potentially contribute to β-cell failure associated with obesity and insulin resistance 
by repressing Hnf1b, the MODY type 5 gene (144). Two other MODY genes, Hnf1a and Neurod1, 
are direct target of miR-24 and mediate its contribution to loss of β-cell function (359). So far, the 
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expression of miR-24 has not been investigated in islets of diabetic donors, but it is increased in 
islets of pre-diabetic and diabetic db/db mice. Furthermore, knockdown of miR-24 rescued β-cell 
dysfunction observed in islets from DIO mice (359), suggesting that this miRNA may be important 
for proper islet function.   
piRNAs  
piRNA expression was also analyzed in pancreatic islets under diabetic conditions. A total of 347 
differentially expressed piRNAs were identified between normoglycemic Wistar rats and GK rats, 
non-obese T2D rats characterized by impaired glucose-stimulated insulin secretion, suggesting a 
possible contribution of piRNAs to β-cell dysfunction. Indeed, increasing the levels of DQ732700 
and DQ746748, two piRNAs enriched in the islets of diabetic GK rats, impaired glucose-stimulated 
insulin secretion in the islet cells of Wistar rats. Furthermore, putative targets of DQ732700 and 
DQ746748 were computationally analyzed and shown to be enriched for genes involved in insulin 
secretion (113). Altogether, these findings suggest that piRNAs may potentially contribute to the 
development of β-cell dysfunction in T2D by regulating gene expression in a miRNA like manner. 
However, the exact molecular mechanisms by which piRNAs regulate insulin secretion remain 
unknown. Additional studies are required to pinpoint the precise contribution of piRNAs in the 
acquisition of specific properties of β-cells.  
tRNA-derived fragments 
The reported roles of tRFs in various cellular processes and the correlation between sperm tRFs 
and metabolic dysfunction, necessitated the analysis of tRFs in pancreatic β-cells. While the 
abundance and the function of tRFs in pancreatic islets remain largely elusive, hypomethylation of 
glutamine tRNA was recently shown to destine the tRNA for fragmentation in human β-cells (50). 
Glutamine tRFs generated via this process were shown to enhance apoptotic pathways, which 
provided the initial evidence of tRF function in β-cells.  
As modification state of tRNAs determines the production of tRFs (41, 198), analyzing tRF 
function in β-cells may shed a light on the role of tRNA modifying enzymes that are dysregulated 
during diabetes. Loss-of-function mutations in TRMT10A, a tRNA methyltransferase, are a 
monogenic cause of early onset T2D (119). While the increased rate of β-cell apoptosis is known 
in the absence of TRMT10A, the underlying molecular link between the enzyme and apoptosis was 
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not understood.  With the use of high-performance liquid chromatography coupled to tandem mass 
spectrometry (LC-MS), it was shown that tRNA methylation of guanine (M1G) is significantly 
reduced in TRMT10A-deficient patients (50). Using primer extension assays, TRMT10A was 
confirmed to methylate glutamine and initiator methionine tRNAs at G9 position. Furthermore, in 
TRMT10A deficient cells specific fragmentation of the glutamine tRNA including the 
hypomethylated 5’ region was observed by Northern Blotting and qPCR. Interestingly, mimicking 
the levels of this glutamine tRF-5, induced apoptosis in the TRMT10A-competent EndoC-H1 
human β-cell line. Reversely, inhibiting glutamine tRF-5 in TRMT10A-deficient EndoC-H1 cells 
reduced apoptosis, suggesting that the apoptotic phenotype observed in TRMT10A-deficient 
patients may result from the activity of glutamine tRF-5.  
This report, in combination with the aforementioned association of tRFs with cytochrome c (41, 
273), suggests that tRFs may be novel regulators of β-cell apoptosis. Further studies in models 
associated with β-cell death, such as T1D may help pinpoint the role of tRFs in β-cells.  
LncRNAs 
Various environmental and genetic factors contribute to the susceptibility of an individual to T2D. 
Interestingly, a large number of T2D-associated common variants that were identified in genome-
wide association studies map to noncoding genomic regions (245). Some of these risk alleles in 
human islets were found to correlate with the expression of lncRNAs (73, 153, 322). The levels of 
several others lncRNAs were reported to be dysregulated in human islet samples diagnosed with 
T2D or impaired glucose tolerance (IGT) compared to non-diabetic donors (8, 73, 221). Of them, 
HI-lnc71/PLUTO and MEG3 were found to be downregulated (8, 138) (see previous Section titled 
“lncRNAs in the control of β-cell functions”).  
 Motterle and colleagues investigated the functional impact on β-cell function and survival 
of lncRNAs dysregulated in T2D mouse models (226). High-throughput RNA-sequencing with de 
novo annotation of islets from diet-induced obese (DIO) mice led to the identification of two β-
cell-enriched and intergenic lncRNA, βlinc2 (XLOC_010971) and βlinc3 (XLOC_013310), whose 
expression levels were correlating with body weight gain and glycaemia levels. Interestingly, 
altered expression of βLINC3 human orthologue was also observed in the islets of T2D donors 
compared to non-diabetic controls, and was negatively correlated with the BMI of the patients. Of 
note, the human ortholog of βlinc2 could not be identified in this particular study. Both βlinc2 and 
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βlinc3 were also found to be upregulated and downregulated, respectively, in islets of overtly obese 
and diabetic leptin-deficient db/db mice, and in control islets exposed in vitro to elevated 
concentrations of glucose or of the saturated fatty acid palmitate. Ex vivo incubation of human islets 
with palmitate reduced also the level of βLINC3. The dysregulation of these lncRNAs could be part 
of the mechanisms leading to β-cell damage in T2D since altered expression of βlinc2 and βlinc3 
in both MIN6 cells and mouse islets favored β-cell apoptosis. 
 The lncRNA GAS5 was also reported to be downregulated in islets of db/db mice (131) 
and in serum samples of T2D donors when compared to non-diabetic control subjects (34). GAS5 
(growth arrest-specific transcript 5) is a non-coding tumor suppressor gene whose expression is 
decreased in diverse cancers (129). GAS5 gene encodes in its exons a spliced long non-coding 
RNA, named lncRNA GAS5, and expresses from its intronic sequences multiple snoRNAs that are 
involved in the biosynthesis of ribosomal RNA (295). Deregulation of GAS5 expression in cancer 
cells affects apoptosis, proliferation, invasion and metastasis of cancer cells (Reviewed in (129)). 
GAS5 could also be of interest in the field of diabetes.  
Downregulation of lncRNA Gas5 in mouse islets or MIN6 cells led to reduce expression of 
the Ins2 gene and the transcription factor Pdx1, NeuroD1 and MafA and an altered insulin secretion 
in response to glucose (131). Inhibition of lncRNA Gas5 did not impact cell survival but induced 
cell cycle G1 arrest. Interestingly, genes related to cell cycle (cyclinD1.3 and cyclinE1.2), and 
insulin secretion (Glut2) were found to be downregulated following GAS5 silencing (131). 
circRNAs 
CircRNA dysregulation has also been observed in the islets of rodent models of T2D. Indeed, ciRS-
7/Cdr1as level is decreased in ob/ob and db/db mouse islets, while that of circHIPK3 is diminished 
in the islets of db/db mice. Interestingly, the islet expression of Hipk3, the parent gene of 
circHIPK3, is also decreased in ob/ob and db/db mice (300) and in humans with T2D (189). Hence, 
it is likely that islet circHIPK3 dysregulation also occurs in T2D patients, and that altered levels of 
both functional circRNAs contribute to β-cell failure in this disease. Unbiased analyses of circRNA 
expression in islets of different rodent models and of human donors are however required to fully 
explore the role of these ncRNAs in diabetes.   
 
 
50 
 
Extracellular non-coding RNAs and islet cells 
NcRNAs exert a broad array of functions inside the β-cells but can also be secreted to send signals 
to other cells. The ncRNAs released from the cells are packaged in vesicle-like structures, such as 
exosomes and microvesicles (118, 294), form complexes with ribonucleoproteins (14, 220, 313, 
325) or are transported by high-density lipoproteins (HDL) (320). For instance, miR-375 was 
recently reported to be released by β-cells and trapped by HDL (283). Once secreted, the ncRNAs 
travel in the bloodstream and in other body fluids and some of them are delivered to recipient cells, 
eventually resulting in gene expression changes (262, 316). NcRNA composition in biological 
fluids reflects ongoing processes and has been suggested to provide information about disease state, 
progression, prognosis and response to therapy (222). Thus, circulating ncRNAs represent 
promising biomarkers to predict and follow the progression of many diseases, including T1D and 
T2D (17, 289).  
Extracellular Vesicles 
The release of extracellular vesicles (EVs) is a highly conserved process used by different 
organisms for intercellular communication (55, 263, 279). EVs are very heterogeneous and differ 
in size and intracellular origin, making their classification and characterization a matter of debate 
(127, 210). In general, EVs are called microvesicles when they are generated by the blebbing of 
the plasma membrane and are larger than 200 nm, while smaller EVs (less than 200 nm) formed 
by the fusion of multivesicular bodies (MVBs) with the plasma membrane are called exosomes or 
small extracellular vesicles (sEV) (156, 260, 318). Study of sEV composition revealed that they 
carry a cargo of diverse biomolecules, including proteins, lipids and nucleic acids, and that their 
content can vary between cells and conditions (61, 127, 155, 171). Importantly, sEV transport 
selected pools of miRNAs and other ncRNAs, such as tRFs, that can be transferred in active form 
to target cells, resulting in changes in the functional properties of the receiving cells (47, 286, 290, 
316). While ncRNAs released in the circulation can be carried by different types of vesicles, most 
studies investigating cell-to-cell ncRNA transfer were performed with EV smaller than 200nm 
isolated by differential centrifugation. Therefore, in the present review will exclusively focus on 
this type of vesicles. 
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Non-coding RNAs delivered to islet cells 
During the initial phases of T1D, immune cells infiltrating the islets of Langerhans were reported 
to release exosomes that shuttle a specific set of miRNAs to β-cells (100). These miRNAs (miR-
142-3p/-5p and miR-155) induce the expression of cytokines and chemokines within the β-cells 
and promote apoptosis of these insulin-secreting cells, without affecting the survival of glucagon-
secreting cells. Injection of a viral construct producing a transcript capable of binding and 
sequestering the miRNAs transferred inside the β-cells decreased by 50% diabetes incidence in 
NOD mice (100) (Fig. 8A). In addition to miRNAs, the exosomes released by T lymphocytes carry 
a variety of other RNA molecules that are likely to be transferred to β-cells during the autoimmune 
reaction. In fact, activated T lymphocytes were very recently reported to produce sEV selectively 
enriched for tRFs (43) suggesting that besides miRNAs, other non-coding RNAs might also be 
transferred to β-cells. 
sEV may also carry signals to β-cells under conditions associated with T2D. Indeed, 
exosome-like vesicles (ELVs) secreted by skeletal muscle of HFD-fed mice were shown to transfer 
specific miRNAs to islet cells and to induce β-cell proliferation (126). A similar effect was obtained 
with hepatocyte-derived EVs from HFD-fed mice, where β-cell proliferation was mediated by miR-
7218-5p carried by these vesicles (85). These discoveries suggest the existence of a sEV-mediated 
crosstalk between skeletal muscle, liver and β-cells playing an important role in compensatory islet 
hyperplasia under conditions of insulin resistance (85, 126). (Fig. 8B). More studies point to a 
contribution of ncRNA cellular exchange through sEV in metabolic homeostasis (reviewed in (102, 
116, 222)). Indeed, administration of plasma exosomes isolated from obese mice induces insulin 
resistance and glucose intolerance in lean mice (35, 36). A similar metabolic effect was observed 
with exosomes, carrying miR-155, released by adipose tissue macrophages from obese mice (342). 
Moreover, exosomes produced by brown adipose tissue were found to transfer to the liver a specific 
set of miRNAs (including miR-99b that targets FGF21) resulting in improved glucose tolerance 
(309). It is therefore tempting to speculate that ncRNAs derived from adipose tissue and 
macrophages may also modulate β-cell metabolism and/or inflammation (116). A complex 
signaling network between key metabolic organs, including liver, pancreas, adipose tissue and 
skeletal muscles, is essential to regulate glucose and lipid metabolism and to achieve metabolic 
homeostasis and energy balance. Dysregulation in this organ crosstalk can lead to obesity and T2D. 
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As described above, accumulating evidence support the importance of extracellular ncRNAs as 
mediators of this crosstalk, complementing the well-known role of hormones and metabolites.   
Transfer of non-coding RNA released by islet cells 
Pancreatic islets and different β-cell lines have been reported to release extracellular vesicles (77, 
101, 176). MiRNAs are horizontally transferred between murine β-cells in vitro through exosomes 
(101). Moreover, exposure of MIN6 β-cells to pro-inflammatory cytokines, affect the composition 
of exosomal miRNAs (exo-miR) and induce apoptosis in the recipient β-cells (101). Islet cell 
exosomes can also actively contribute to the crosstalk with immune cells and stimulate their 
activation during T1D pathogenesis (Fig. 8A). Day’s group was the first to show that insulinoma-
released exosomes can activate autoreactive Th1 cells (288) and marginal zone (MZ)-like B cells 
(23) in pre-diabetic NOD mice. In vivo experiments revealed that immunization with these 
exosomes accelerates insulitis development in non-obese diabetes-resistant (NOR) mice (288). In 
a follow up study, they demonstrated that exosomes released by islet mesenchymal stem cells (i-
MSCs) are able to activate autoreactive B and T cells in NOD mice and increase their IFN-γ 
production (259) (Fig. 8A).  More recently, Rutman and colleagues demonstrated that human islet 
exosomes are internalized by monocytes and B cells, induce T-helper cytokine production and T- 
/ B-cell proliferation (272).  However, the cargo of these exosomes was not analyzed. Thus, the 
potential role of ncRNAs in the observed outcomes remains to be demonstrated. 
Exosomal miRNA transfer may also favor islet vascularization and engraftment following 
transplantation in T1D patients. Indeed, Figliolini and colleagues reported that human islets release 
sEV containing miR-27b, miR-126, miR-130 and miR-196 and capable of promoting migration, 
proliferation and survival of islet endothelial cells (IEC) and to induce the expression of pro-
angiogenic and anti-apoptotic factors (77). Interestingly, endothelial progenitor cells (EPC) were 
also found to secrete sEV favoring insulin release and β-cell survival of human islet cells (32). In 
vivo, sEV from EPC enhanced the vascularization of human islets xenotransplanted in SCID mice. 
However, sEV collected from EPC deficient for the miRNA processing enzyme Dicer1 exerted 
reduced proliferative and angiogenic effects on IEC, suggesting that miRNAs are important players 
in this vascularization process resulting from the crosstalk between islet and endothelial cells (32).  
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The use of non-coding RNAs released by β-cells as biomarkers 
Since they are stable, resistant to long term storage conditions and can be readily detected in 
different body fluids, circulating miRNAs have been suggested to represent a novel class of 
biomarkers capable of predicting the appearance and/or the clinical progression of different forms 
of diabetes (reviewed in (222, 281)). However, to have clinical significance, biomarkers need to be 
disease-specific, highly reproducible and sensitive. Despite all efforts made by the scientific 
community, a specific and unambiguous miRNA signature predicting T1D or T2D development 
or outcomes is not yet available. In the present review, we describe the most promising strategies 
and we highlight the remaining challenges for the clinical implementation of circulating ncRNAs 
as diabetes biomarkers. For an exhaustive list of the studies that addressed this topic, we refer the 
reader to recent reviews (222, 281). 
Since miR-375 is highly enriched in pancreatic islet cells, measurements of circulating 
levels of this miRNA stand out as a very attractive opportunity to monitor β-cell damage. Indeed, 
elevated levels of miR-375 were detected in blood samples of streptozotocin-treated mice and NOD 
mice following β-cell death at diabetes onset (68). However, analysis performed in β-cell specific 
mir-375 KO mice demonstrated that less than 1% of plasma miR-375 originates from the insulin-
secreting cells (173). Thus, the contribution of β-cells to the total pool of circulating miRNAs is 
likely to be marginal. In sera of children newly diagnosed with T1D, miR-375 was reported to be 
increased (166), not changed (67) or even decreased (204). In one study, plasma miR-375 levels 
were found to be predictive of residual β-cell function measured by C-peptide released after a meal 
(275). On the contrary, increased levels of plasma miR-375 following islet transplantation 
correlated with lower islet yield and poor transplant outcomes (265, 277). Taken together, these 
results highlight the potential lack of reproducibility among studies when measuring global 
circulating levels of ncRNAs.  
Specific analysis of ncRNA content of sEV in plasma or serum samples may be an 
interesting alternative to global profiling. sEV are released by regulated processes and their cargo 
varies depending on physiological and pathophysiological conditions. Indeed, human islets 
exposed to pro-inflammatory cytokines and/or hypoxia released a miRNA cargo that differs from 
control conditions (278). Interestingly, some of these sEV miRNAs were detected solely in the 
plasma of streptozotocin-treated mice transplanted with human islets and in the blood of recently 
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transplanted patients, suggesting a potential use as diagnostic biomarkers of β-cell stress after islet 
transplantation.  
To circumvent the limited contribution of β-cells to total circulating RNA molecules,    
Vallabhajosyula and colleagues have recently described a method to specifically isolate islet-
derived exosomes in the context of islet transplantation, based on differences between donor HLA 
and recipient HLA, in both xenotransplantation (human/ mouse) and allotransplantation (human/ 
human) (317). Exosomes released by transplanted islets could be purified from recipient blood 
samples and characterized by proteomic and miRNA profiling. Interestingly, the amount of 
exosomes originating from transplanted islets and their RNA and proteomic signatures changed 
during rejection, underlying their potential utilization to monitor graft outcome (317). This strategy 
is very promising and the identification of additional markers specifically present at the surface of 
exosomes released by β-cells would enable their purification from blood samples and would open 
the door to the discovery of new miRNAs as specific β-cell biomarkers. 
Alternatively, other ncRNAs could potentially be used as biomarkers. For example, the expression 
of lncRNAs is known to be more tissue- and stage-specific compared to coding genes and miRNAs 
(56, 58). Thus, they may better mirror β-cell dysfunction and failure during diabetes development 
(270). Other types of ncRNAs, including tRFs or circRNAs, will also have to be considered (334, 
352). 
The therapeutic potential of ncRNAs 
As highlighted in the previous sections, there is growing evidence that different classes of ncRNAs 
are directly involved in the control of islet function and in diabetes development. Indeed, 
experimental strategies permitting to manipulate the level of selected ncRNAs in animal models 
can successfully prevent or treat the disease or its complications (reviewed in (169, 261)). Thus, 
ncRNAs hold a strong therapeutic potential and are attractive targets for the design of new 
pharmaceutical principles for diabetes treatment. However, translating the findings obtained in 
animal models to the clinics is a major challenge that faces several important obstacles. Strategies 
permitting to efficiently modulate the level of ncRNAs are already available. However, these 
strategies have major drawbacks and their use in humans cannot yet be envisaged. One of the 
approaches available to control the activity of ncRNAs takes advantage of sense or antisense 
oligonucleotide derivatives that mimic or block the selected ncRNA (271, 319). Although these 
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molecules can be modified to increase their stability and promote their transfer inside the tissues, 
the main obstacle for the usage of these molecules is that they cannot be specifically targeted to 
selected islet cells. Thus, this approach is likely to result in unacceptable side effects. An alternative 
strategy allowing to circumvent this problem is based on the use of viral constructs driven by cell-
specific promoters. These constructs can be designed to either overexpress the ncRNA (199) or to 
produce transcripts capable of interfering with the activity of the selected ncRNA (63). Although 
these strategies have already been successfully applied to modulate the activity of miRNAs in 
rodent islet cells (100, 123, 228), the use of viral constructs that chronically modulate the level of 
ncRNAs to treat diabetes in humans would raise major safety concerns.  
There is no doubts that ncRNAs hold a great potential for the treatment of diabetes but the 
tools presently available to modulate the activity of these non-coding transcripts are not appropriate 
for therapeutic usage in human. New approaches allowing an efficient delivery of molecules, 
including RNA derivatives, to specific target cells are currently intensively investigated. Thus, 
there is hope that in the near future we will dispose of better approaches to efficiently and safely 
deliver molecules capable of correcting the activity of selected ncRNAs to islet cells. This would 
be instrumental to open the way to the design of therapeutic tools aiming at treating diabetes by 
restoring proper ncRNA function.        
Conclusion 
The discovery that a large fraction of the mammalian genomes is transcribed and generates a 
plethora of ncRNAs with regulatory functions opened a new era in the elucidation of the 
mechanisms underlying the development of most human diseases, including diabetes mellitus. 
Fifteen years of intense investigations permitted to obtain an exhaustive picture of the miRNAs 
expressed in α- and β-cells and to identify changes in the miRNA profile occurring in association 
with obesity, inflammation and diabetes. The involvement of these small ncRNAs in all aspects of 
islet biology is now well established and there are no doubts that dysregulation of important 
miRNAs can contribute to the development of different forms of diabetes. Strategies to correct the 
level of dysregulated miRNAs are emerging and may soon permit the design of new therapeutic 
principles to prevent or treat diabetes. The presence of miRNAs in plasma and other body fluids 
prompted many groups to assess the value of these circulating ncRNAs as biomarkers of β-cell 
function and/or loss. However, because of the heterogeneous origin of the circulating miRNAs, 
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measurements of the total pool of blood miRNAs appear to be inappropriate to detect specific 
changes occurring in β-cells. In the future, approaches permitting the isolation of miRNAs 
selectively released by β-cells will probably permit to overcome this obstacle.        
It has now become clear that, beside miRNAs, islet cells and, in particular β-cells, express 
a large number of other non-coding transcripts, including piRNAs, tRFs, snoRNAs, lncRNAs and 
circRNAs. These classes of ncRNAs are less well characterized than miRNAs. However, there is 
already evidence indicating that these newly discovered transcripts play important roles in the 
differentiation and function of islet cells and that they can be dysregulated under conditions 
associated with diabetes development. We are still learning how these ncRNAs are generated and 
how they mediate their activities inside the cells. Moreover, we are only beginning to understand 
the potential interactions existing between these different classes of ncRNAs. Answering these 
questions will provide a more complete view of the complex regulatory networks governing islet 
cell functions under normal and disease conditions. The coming years promise to unveil new 
secrets about the fascinating RNA world hidden inside the cells, hopefully providing new ground 
to elucidate the causes of diabetes mellitus and to design better treatments for diabetic patients.  
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Figure legends  
Fig. 1 | Regulation of β-cell mass over lifetime. The functional β-cell mass is regulated by 
different processes over the course of a lifetime. During embryonic development and the neonatal 
period, expansion of the β-cells is critical for the acquisition and the maintenance of a fully 
functional β-cell mass. Adverse conditions limiting β-mass expansion during these critical periods 
predispose individuals to diabetes later in life. Pancreatic β-cells can be the target of an autoimmune 
attack. Immune cells infiltrate the islets and selectively kill the β-cells, leading to a near complete 
loss of insulin-secreting cells and the appearance of Type 1 diabetes. Throughout life, several 
mechanisms favor the expansion of the functional β-cell mass during pregnancy or in obese 
individuals to compensate for insulin resistance of peripheral tissues. Type 2 diabetes develops if 
the functional β-cell mass fails to adapt to cover the increased insulin needs. Lastly, ageing and β-
cell senescence can reduce the capacity to compensate for insulin resistance.   
 
Fig. 2 | Relative amounts of RNA transcripts in human and mouse cells. Pie chart representing 
the proportion of different RNA classes compared to the total number of annotated genes in A) 
Human (60’603 genes) or B) Mouse (55’487 genes). Data obtained from Gencode 31. (Abv: 
lncRNAs = long-non coding RNAs, miRNAs = microRNAs, snoRNAs = small nucleolar RNAs, 
snRNAs = small nuclear RNAs, ncRNAs = non-coding RNAs).  
 
Fig. 3 | Classification of RNAs. RNA molecules can be divided in two categories depending on 
their ability to code (coding RNA) or not (non-coding RNA) for proteins. Non-coding RNA 
transcripts are classified based on their function (rRNA = ribosomal RNA, tRNA = transfer RNA) 
or on their length (shorter or longer than 200 nucleotides). The short RNA families include 
snoRNAs (small nucleolar RNAs), snRNAs (small nuclear RNAs), siRNAs (small interfering 
RNAs), miRNAs (microRNAs) and piRNAs (PIWI-interacting RNAs). The long non-coding RNA 
family is further subdivided based on the shape of the RNA molecules: linear long-non coding 
RNA (lncRNA) or circular RNA (circRNA). Of note, tRNA molecules can be cleaved to generate 
fragments (tRF) that share some properties with other short ncRNAs. 
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Fig. 4 | Generation and classification of tRFs. Endonucleic cleavage of mature tRNAs generates 
a diverse range of tRFs. Various endonucleases including Dicer generate short tRFs (12-20 
nucleotides) at either arms of the tRNAs. Alternatively, Angiogenin cleaves tRNAs at the 
anticodon loop, generating tRNA halves (32-50 nucleotides, also known as tiRNAs). A double 
cleavage along the length of tRNAs can generate internal tRNA fragments (16 nucleotides or 
longer, also known as i-tRFs). 
 
Fig. 5 | Classification of lncRNAs based on their genomic proximity to protein-coding genes. 
A) Long intergenic non-coding RNAs (lincRNAs) are located in intergenic regions. They are 
situated at more than 1 kb distance from the nearest protein-coding genes. B) The other classes of 
long non-coding RNAs (lncRNAs) are located in the vicinity of protein-coding genes and are 
named based on how their exons are positioned on the genome with respect to the exons of the 
mRNA and on the direction of transcription: overlapping, intronic, cis-antisens or bidirectional. 
 
Fig. 6 | Examples of mode of action of lncRNAs in β-cells. A) The lncRNA PLUTO acts on 3D 
chromatin organization to favor the transcription of PDX1 by bringing in close proximity the PDX1 
promoter with its enhancer cluster. B) The lncRNA Meg3 inhibits EZH2-mediated methylation of 
Rad21, Smc3 and Sin3α promoters, triggering the expression of these transcription factors and, 
therefore, resulting in the inhibition of MafA expression. C) The lncRNA H19 sequesters let-7 
members to prevent the repression of target genes of these miRNAs, leading to activation the 
PI3K/AKT pathway. (Abv: lncRNA = long non-coding RNA, miRNA = microRNA, PI3K = 
phosphatidylinositol 3-kinase) 
 
Fig. 7 | Formation of circular RNAs in eukaryotic cells. Eukaryotic circular RNAs can be 
generated from introns (grey) and/or exons (colored) of pre-mRNAs. Circular intronic RNAs (left) 
arise from introns circularized at the 5’ and branchpoint (bp) nucleotides by a 2’-5’ junction during 
linear splicing. These branched circular introns have a linear 3’ tail and are known as lariats. Intron 
lariats can be debranched and rapidly degraded or escape debranching, lose their tail, and turn into 
stable circular intronic RNAs. Instead, circular exonic and exonic-intronic RNAs (right) can 
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contain one or more exons and/or introns and are produced by backsplicing of an upstream 3’ splice 
site and a downstream 5’ splice site circularized by a 3’-5’ junction. 
 
Figure 8 ǀ Exosome cross-talk in the context of type 1 and type 2 diabetes. A) In the context of 
T1D, islet Mesenchymal Stem Cells (i-MSC) and β-cells secrete exosomes that activate T-cells and 
B-cells. Pancreatic islet-cells produce exosomes that can horizontally transfer genetic material to 
adjacent islet-cells and endothelial cells. Infiltrated T-cells transfer specific miRNAs via exosomes 
to β-cells. B) In the context of T2D, muscle and hepatic exosomes deliver miRNAs to pancreatic 
islet cells. Exosomes secreted from Adipose Tissue Macrophages (ATMs) transfer miRNAs to 
insulin target tissues. Adipose tissue release exosomes containing miRNAs to liver and skeletal 
muscle. A-B) Pancreatic islet exosomes and ncRNAs that are released in the blood stream represent 
potential biomarkers for T1D and T2D. 
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Table 1: List of ncRNAs investigated in pancreatic β-cells* 
ncRNA Animal/cell models Expression/ functional effects / mechanism of action References 
    
piRNA    
DQ732700 and Islets of GK rats Increased levels of DQ732700 and DQ746748 (113) 
DQ746748 Overexpression in rat islets Reduction of GIIS  
    
snoRNAs    
U32a, U33, U34, U35a Rpl13a-snoless mice Increased GIIS in vivo and ex vivo (177) 
  Enhanced glucose tolerance  
  Remain normoglycemic in respose to STZ treatment,  
or when crossed with Akita or NOD mice 
  Rpl13a-snoless islets are resistant to oxidative stress  
snoRNAs from Snord116 Snord116p-/m+ mice Defect in proinsulin processing (31) 
  Secretion of a higher proinsulin/C-peptide ratio  
  Reduction of mean islet size (30) 
  Increased number of polyhormonal islet cells  
  Lower levels of Pdx1, Pax6 and Nkx6.1 in adult islets  
    
tRFs    
5'-tRNAGln Augmentation in EndoC-βH1 Induces apoptosis  (50) 
 Inhibition in EndoC-βH1 Prevents apoptosis induced by TRMT10A deficiency  
    
lncRNAs    
βlinc2 (XLOC_010971) Islets of DIO and ob/ob mice Increased levels of βlinc2 (vs normal diet and +/+, respectively) (226)  
 Downregulation in mouse islets and 
MIN6 cells 
Favors β-cell apoptosis  
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βlinc3 (XLOC_013310) Islets of T2D donors and DIO mice 
(vs normal diet) 
Increased levels of βlinc3 (226) 
 Islets of db/db mice (vs db/+) Decreased levels of βlinc3  
 Downregulation in mouse islets and 
MIN6 cells 
Favors β-cell apoptosis  
GAS5 Islets of T2D donors and db/db 
mice (vs C57BL/KsJ) 
Decreased levels of GAS5 (34, 131)  
 Inhibition of GAS5 in MIN6 cells 
and/or mouse islets 
Reduction of GIIS, insulin content and Ins2, MafA and Pdx1 
expression 
(131) 
  Cell cycle arrest without impact on cell survival  
H19 Islets of db/db, ob/ob and DIO mice Upregulation of H19 (vs db/+, +/+ and normal diet, resp.) (276) 
 Rat islet maturation Decreased expression of H19 in adult vs P10 pups  
 Islets from LP pups Downregulation of H19 in P10 pups born from dams  
fed low-protein diet vs normal diet 
 Deregulation of H19 in adult and 
P10 rat islets 
Regulation of β-cell proliferation by sponging let-7 family members  
and favoring PI3K-AKT signaling pathway 
HI-LNC15 / βlinc1 Downregulation in EndoC-βH1 Dysregulation of genes related to NKX2.2 regulatory network (13) 
 Whole-body KO mice Reduction in β-cell mass at birth  
  Glucose- and insulin-intolerant at adult age  
HI-LNC25 Downregulation in EndoC-βH1 Favors GLIS3 expression (221)  
HI-LNC78 Downregulation in EndoC-βH1 Reduction of insulin content and GIIS (221) 
Lnc03 (Gm16308) Islets from pregnant mice Upregulation of Lnc03 (vs non-pregnant) (293) 
 Downregulation of Lnc03 in mouse 
islets  
Decreases β-cell proliferation induced by prolactin  
lncRNA-1 gm5970 Islets of 8 wks NOD mice (vs 4 
wks, and compared to SCID)  
Increased levels of lncRNA-1 (225)  
 Mouse islets/MIN6 exposed to cyt. 
mix 
Increased levels of lncRNA-1  
 Upregulation of lncRNA-1 in 
MIN6 and mouse islets 
Induces β-cell apoptosis and favors NFκB translocation to the 
nucleus 
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lncRNA-2 AI451557 Islets of 8 wks NOD mice  
(vs 4 wks, and compared to SCID)  
Increased levels of lncRNA-2 (225)  
 Mouse islets/MIN6 exposed  
to cyt. mix 
Increased levels of lncRNA-2  
 Upregulation of lncRNA-1 in 
MIN6 and mouse islets 
Induces β-cell apoptosis   
lncRNA-3 BC002288 Islets of 8 wks NOD mice  
(vs 4 wks, and compared to SCID)  
Increased levels of lncRNA-3 (225)  
 Mouse islets/MIN6 exposed to cyt. 
mix 
Increased levels of lncRNA-3  
 Upregulation of lncRNA-1 in 
MIN6 and mouse islets 
Induces β-cell apoptosis   
lncRNA-4 gm16675 Mouse islets/MIN6 exposed to cyt. 
mix 
Increased levels of lncRNA-4 (225)  
 Upregulation of lncRNA-1 in 
MIN6 and mouse islets 
Induces β-cell apoptosis   
MEG3 Islets of T2D donors Downregulation of MEG3 (138)  
 Islets of db/db and NOD mice 
(compared to Balb/c) 
Downregulation of MEG3 (326, 343)  
 Balb/c mice injected with siMeg3 Impaired glucose tolerance (326, 343)  
  Reduction of serum insulin levels in response to IPGTT  
 Inhibition of Meg3 in MIN6/mouse 
islets 
Reduction of Ins2 expression and insulin secretion (326, 343)  
  Meg3 favors Rad21, Smc3 and Sin3a expression which repress MafA  
PLUTO (HI-LNC71) T2D and IGT donors Downregulation of PLUTO expression (8) 
 Downregulation in EndoC-βH1  
and human islets 
Reduced PDX1 expression by affecting chromatin organization  
 Downregulation in EndoC-βH1 Decreased insulin content and consequent impaired GIIS  
    
circRNAs    
circAFF1 Downregulation in rat islets Induced apoptosis  (300)  
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circARHGAP12 Islets of 8 wks NOD mice (vs 4 
wks, and compared to SCID) 
Decreased levels of circARHGAP12 (300) 
ciRS-7/Cdr1as Islets of ob/ob and db/db mice Decreased levels of ciRS-7/Cdr1as  (300) 
 Downregulation in rat islets Tendency to inhibit GIIS  
  Reduce β-cell proliferative capacity  
 Overexpression in MIN6  Slight increase in GIIS (340) 
 and mouse islets Higher insulin content  
  Upregulation of Myrip and Pax6 expression by sponging miR-7  
circHIPK3 Islets of db/db mice Decreased levels of circHIPK3 (300)  
 Downregulation in rat islets Inhibition of GIIS  
  Reduction of β-cell proliferative capacity  
  Rise in the apoptotic rate  
* For miRNAs, readers are referred to dedicated review (72, 78, 169)  
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Table 2: Summary of the bioinformatic tools developed for ncRNA identification and for target prediction 
Category Tool Type Last update Brief description URL Ref. 
       
miRNA 
identification 
MiRscan Web server 2003 Based on RNA fold and evolutionarily 
conserved  miRNAs 
http://hollywood.mit.edu/mirscan/ (186) 
 miRseeker Method 2003 Based on M-fold and evolutionarily conserved miRNAs 
- (165) 
 ProMir II Web server 2006 HMM-based tool; predicts conserved and non-
conserved miRNAs 
- (230) 
 MiRRim Method 2007 HMM-based tool; high-performance 
identification of those clustering with known 
miRNAs 
- (307) 
 HHMMiR Software 2009 Based on hierarchical HMM; predicts de novo 
miRNA hairpins in the absence of evolutionary 
conservation 
http://www.benoslab.pitt.edu/kadriA
PBC2009.html 
(135) 
 SSCprofiler Web server 2009 Based on profile HMM; identifies novel 
miRNAs located in cancer-associated genomic 
regions 
http://mirna.imbb.forth.gr/SSCprofile
r.html 
(240, 241)  
 BayesmiRNAfind Web server 2006 NBC-based program - (345) 
 MatureBayes Web server with 
script code 
2010 NBC-based program http://mirna.imbb.forth.gr/MatureBay
es.html 
(91) 
 MiRFinder Software 2007 SVM-based tool; performs pair-wise genome 
alignments between related species; fails to 
detect species-specific pre-miRNAs 
https://www.bioinformatics.org/mirfi
nder/ 
(117) 
 miRDeep/ 
miRDeep2 
Software 2012 Predicts known and novel miRNAs from NGS 
data 
https://www.mdc-berlin.de/ 
content/mirdeep2-documentation 
(81, 82)  
 miRanalyzer Web server 2013 Predicts known and novel miRNAs from NGS 
data 
https://bioinfo5.ugr.es/srnatoolbox/sr
nabench/ 
(109, 110) 
 miReader Software 2013 Identifies mature miRNAs directly from NGS 
data without the need for genomic sequences 
- (128) 
miRNA target 
prediction 
TargetScan Web server with 
script code 
2018 Uses the context++ model to predict the most 
effective canonical targeting 
http://www.targetscan.org/vert_72/ (3) 
 miRanda Software 2010 Recognizes target sites using features like 
sequence complementarity between mature 
miRNA and the free energy of the duplex 
http://www.mirtoolsgallery.org/miRT
oolsGallery/node/1055 
(66) 
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 PITA Software 2008 Takes in to account target site accessibility https://genie.weizmann.ac.il/pubs/mir
07/ 
(147) 
 PicTar Web server 2007 Detects conserved sites across multiple species 
using a pair-wise alignment algorithm 
http://pictar.mdc-berlin.de/ (168) 
 RNA22 Web server 2015 Pattern-based program to find miRNA binding 
sites without cross-species sequence 
conservation filtering 
https://cm.jefferson.edu/rna22/  (190) 
 RNAhybird Web server with 
script code 
2006 Based on free energy of miRNA:mRNA 
duplexes 
https://bibiserv.cebitec.uni-
bielefeld.de/rnahybrid 
(161) 
piRNA 
identification 
piRNApredictor Software 2011 Based on a k-mer scheme to identify piRNA 
sequences, relying on the training sets from non-
piRNA and piRNA sequences  
- (350) 
 Piano Software 2014 Based on piRNA-transposon interaction 
information 
http://www.insect-
genome.com/links/piano.php 
(323) 
 Luo method Software 2016 Transposon-derived piRNA prediction https://journals.plos.org/plosone/artic
le?id=10.1371/journal.pone.0153268 
(196) 
 Li method Software 2016 Based on a genetic algorithm weighted 
ensemble method for predicting transposon-
derived piRNAs 
https://github.com/zw9977129/piRN
APredictor 
(181) 
 2L-piRNA Web server 2017 Identifies whether a query RNA molecule is 
piRNA and if it instructs target mRNA 
deadenylation 
http://bioinformatics.hitsz.edu.cn/2L-
piRNA/ 
(188) 
piRNA target 
prediction 
pirScan Web server 2018 Identifies C. elegans piRNA-targeting sites 
within a given mRNA or spliced DNA sequence 
http://cosbi4.ee.ncku.edu.tw/pirScan/ (337) 
 piRTarBase Web server 2018 Integrative platform that identifies functional 
piRNA target sites by taking in to account 
multiple information 
http://cosbi6.ee.ncku.edu.tw/piRTarB
ase/ 
(336) 
tRNA 
fragment 
identification 
MINTmap Software 2017 Based on a sequence-centric scheme for labeling 
tRFs to calculate and report raw and normalized 
abundances for the discovered tRFs 
https://github.com/TJU-CMC-
Org/MINTmap/  
(191) 
 tRF2Cancer Web server 2016 Based on a binomial test to distinguish genuine 
tRFs from degradation fragments 
http://rna.sysu.edu.cn/tRFfinder/ (354) 
circRNA 
identification 
circRNA_finder Software 2018 Based on STAR-mapped reads https://github.com/orzechoj/circRNA
_finder 
(331) 
 CIRCexplorer2 Software 2019 Based on Tophat-mapped reads https://github.com/YangLab/CIRCex
plorer2 
(349) 
 CIRI2 Software 2017 Based on BWA-mapped reads https://sourceforge.net/projects/ciri/fi
les/CIRI2/ 
(89) 
 find_circ Software 2017 Based on Bowtie2-mapped reads https://github.com/marvin-
jens/find_circ 
(215) 
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 MapSplice Software 2016 Based on Tophat-mapped reads http://www.netlab.uky.edu/p/bioinfo/
MapSplice2 
(324) 
 ACFS Software 2017 Based on BWA-mapped reads https://github.com/arthuryxt/acfs (344) 
 DCC Software 2019 Based on STAR-mapped reads https://github.com/dieterich-lab/DCC (42) 
 KNIFE Software 2017 Based on Bowtie2-mapped reads https://github.com/lindaszabo/KNIFE (303) 
 Uroborus Software 2018 Based on Tophat-mapped reads https://github.com/WGLab/UROBO
RUS 
(297) 
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